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Group testing is the process of pooling samples (e.g., blood, chemical compounds) 
from multiple sources and testing the pooled material for some binary 
characteristic. It is used in pathogen screening for humans and animals, drug 
discovery studies, electrical systems testing, and many other applications. Group 
testing has traditionally been used for two main types of investigations: 1)the 
identification of positive specimens and 2) the estimation of a characteristic’s 
prevalence in a population. This dissertation focuses on the identification process. 
We propose new identification procedures that exploit the heterogeneity among 
samples in order to reduce the number of tests needed to detect the binary 
characteristic. We first propose the “ordered halving” procedure which is shown 
to reduce the expected number of tests in comparison to current implementations 
of halving. Next, we generalize our proposals to a class of hierarchical group 
testing procedures. Our proposals result in significant reductions in the expected 
number of tests while also maintaining accuracy at levels similar to those 
procedures which do not account for heterogeneity.  
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Chapter 1: Introduction 
1.1 Foundations of group testing 
In the four years after the bombing of Pearl Harbor, the US military put almost 
12 million men in uniform (Flynn 1993, page 53). As part of the build-up process, 
all new men needed to be screened to determine their fitness for combat. This 
screening process involved testing for various diseases, including syphilis. As 
detailed in Du and Hwang (2000), a group of government economists in 1942 or 
1943 were disappointed at the wastefulness that came from individually testing 
every man for syphilis. These economists subsequently developed the idea of 
group testing to reduce the time and costs associated from testing. Among them, 
Robert Dorfman subsequently published this idea.  
Dorfman (1943) proposed that blood specimens from a set of individuals could 
be combined into a single group specimen. If the group tested negative (syphilis 
was not present), all individuals within the group would be declared negative. If 
the group tested positive (syphilis was present), all individuals would be retested 
individually in order to decode the positives from the negatives. Because syphilis 
had a low prevalence, it was hoped that the number of tests resulting from group 
testing would be less than from testing each person individually.  
Group testing ultimately was not used for the military induction screening (Du 
and Hwang, 2000). The group testing idea may have disappeared if not for a 
problem described in Feller (1950, p. 189; 1957, p. 225) which started others 
thinking about how group testing may be done more efficiently. We next give 
details of Dorfman’s original proposal and of others’ subsequent proposals. 
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1.1.1 Dorfman (1943) 
Consider a group of I individuals where specimens are pooled. If the probability 
each individual is positive is denoted by p and we assume that individuals 
screened represent a random selection, the probability of no positive individuals 
in the group is (1 – p)I. The probability that a group tests positive is then 1 – (1 
– p)I. This leads to an expected number of tests of 1 + I{1 – (1 – p)I} for one 
group, and an expected total number of tests across all groups formed of size I to 
be N/I + N{1 – (1 – p)I}, where N is the number of individuals screened.  
Using these formulas, Dorfman (1943) showed a significant cost savings from 
using his proposal rather than individual testing. Dorfman presented tables to 
provide the most efficient group size given a value for p and concluded that 
group testing is only effective if the characteristic of interest has a small 
prevalence. Watson (1961) later showed that the optimal group size is 
approximately p-1/2.  
1.1.2 Sterrett (1957) 
Sterrett (1957) proposed a retesting algorithm for screening blood specimens that 
did not immediately test each individual in a positive group, but instead started 
testing individual specimens one at a time (chosen at random) until the first 
positive individual was found. Once this positive individual was found, the 
remaining individuals would be retested in a new group. If this new group tested 
negative, these remaining individuals would be declared negative. However, if this 
new group tested positive, the same one-by-one testing process would begin again 
with these remaining individuals to decode the positive individuals from the 
negative individuals. For situations with a reasonably chosen initial group size 
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and small p, this retesting procedure works well because there is most likely only 
one positive individual in a group. 
1.1.3 Group splitting procedures 
Sobel and Groll (1959) presented several industrial situations where group testing 
is useful as well, including the testing for a faulty device and the testing of 
electrical devices in series (e.g., Christmas tree lights). They also proposed a 
retesting algorithm that successively splits positive groups into two subgroups. If 
one of these subgroups tested positive, it can be split again and so on until only 
single units are left to be tested. Their algorithm used the knowledge of the 
prevalence to optimize the size of each retesting subgroup. If the prevalence was 
unknown, they suggested that the groups be split in half (two equally sized 
subgroups). This is what we refer to as halving.   
Subsequent papers by others further expanded upon the group splitting 
proposals. These papers include: Sobel and Groll (1966) expanded on the idea of 
halving from their 1959 paper, Hwang (1972) examined a binary splitting 
algorithm of which halving could be considered a subset, and Litvak et al. (1994) 
considered halving in the presence of testing error with the possibility of 
confirmation testing considered. 
1.1.4 Non-hierarchical procedures 
Li (1962) categorized group testing procedures by the number of possible stages 
(i.e., steps, cycles) and by hierarchical (adaptive) or non-hierarchical (non-
adaptive) approaches. Any procedure that uses information from a previous stage 
to determine the testing pattern on a subsequent stage is considered hierarchical. 
Dorfman’s procedure is an example of a simple hierarchical, two-stage procedure 
because the results from the initial testing of groups are needed to decide if 
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individual testing is needed. Sterrett is an example of a hierarchical procedure 
with a non-fixed number of stages, because the number of stages is unknown at 
the start.  
Non-hierarchical examples include standard individual testing and array 
(matrix) testing. Individual testing is a one-stage procedure because it takes just 
one step of testing to determine who is positive and who is negative. Array 
testing (Phataford and Sudbury, 1994) involves organizing individual specimens 
into a grid and pooling individuals for testing by both rows and columns. This 
leads to each individual being within two groups at the beginning. If an 
individual is in a row and column that both test positive, it could be classified as 
positive. Thus, there is only one stage of testing. However, when more than one 
row and more than one column test positive, ambiguities exist concerning which 
individual is positive or negative, so additional individual testing may be 
performed in these cases. Subsequent work in array testing after Phataford and 
Sudbury (1994) include: Berger et al. (2000) who proposed array testing in more 
than two directions without testing error, Kim et al. (2007) who incorporated 
testing error and a master array pool, and Kim and Hudgens (2009) who 
developed a three-dimensional array procedure with testing error. 
1.1.5 Other approaches 
Dorfman (1943) stated his proposal in probabilistic terms, “we have a population 
expressing a trait with probability (or prevalence rate) of p,” and the efficacy of 
his procedure is determined by the expected number of tests needed to decode 
positive and negative individuals. Li (1962) and Katona (1973) looked at group 
testing in combinatorial terms by trying to optimally find a subset of d positives 
from an initial set of size n. For a detailed exploration of combinatorial group 
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testing, see Du and Hwang’s (2000) textbook on the subject. We focus on 
probabilistic group testing, because we consider situations where individual 
probabilities of positivity may be different from an overall prevalence rate. 
1.2 Testing error 
While Dorfman (1943) did not consider testing error, he did mention the 
possibility of it in his paper. Most disease testing situations need to account for 
testing error because assays are usually not 100% correct. Watson (1961) is 
possibly the earliest paper to consider testing error in a group testing context. 
Watson looked at experimental error arising where significant factors in an 
experimental design were identified. Also, Graff and Roeloffs (1972) looked at the 
effect testing error could have on group testing in terms of the number of tests 
and associated costs. Incorporating testing error into an analysis is now standard 
for disease testing situations.  
Testing errors occur when positive items are incorrectly identified as negative 
or vice versa. Altman and Bland (1994a, b) define the sensitivity (Se) as the 
proportion of true positives identified by a test and the specificity (Sp) as the 
proportion of true negatives correctly identified. Typically, for disease diagnostic 
tests, the Se and Sp values are given by an assay manufacturer or validated by a 
laboratory using the assay. In these settings, Se and Sp are actually statistics 
summarizing a selected set of specimens with known positive and negative values. 
However, currently in most applications, Se and Sp are treated as constants, and 
we will do the same within this dissertation.   
Altman and Bland (1994a, b) also contend that it is desirable to know how 
well a diagnostic test does at correctly diagnosing subjects. Corresponding 
measures are the positive predictive value (PPV), which is the proportion of 
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positive test results that correctly indicate a true positive status, and the 
negative predictive value (NPV), which is the proportion of negative test results 
that correctly indicate a true negative status. PPV and NPV can then be 
calculated as PPV = Sep/[Sep +(1 – Sp)(1 – p)] and NPV = Sp(1 – p)/[(1 – Se)p + 
Sp(1 – p)] by using Bayes’ rule.  
In the context of group testing, an assay may be applied multiple times to the 
same specimen (either in a group or individually) to determine its positive or 
negative status. The Se and Sp values are often treated as the same for each 
testing stage (e.g., for Dorfman’s procedure, Se is the same for the initial group 
test and subsequent individual tests), and we will do the same within this 
dissertation. However, because a specimen may be tested multiple times, its 
probability of being correctly diagnosed through the group testing process is no 
longer Se and Sp. Instead, Johnson et al. (1991) define the pooling sensitivity 
(PSe) and pooling specificity (PSp) to measure the correctness of the group testing 
procedure’s classification of individuals. The pooling sensitivity is the probability 
that an individual is categorized as positive by a particular group testing 
procedure given that individual is truly positive. The pooling specificity is defined 
in a similar manner for the negative individuals. Kim et al. (2007) use PSe and 
PSp then to define the pooling positive predictive value (PPPV) and pooling 
negative predictive value (PNPV) for a given group testing procedure as 
(1 )(1 )
e
e p
pPS
PPPV
pPS p PS
= + - -  
and 
(1 )
,
(1 ) (1 )
p
p e
p PS
PNPV
p PS p PS
-= - + -  
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again through an application of Bayes’ rule.  
The assumption of identical Se and Sp values at multiple stages of group 
testing is often used due to the work of papers such as Kline et al. (1989), Tu et 
al. (1995), and Soroka et al. (2003). These papers showed that for group sizes up 
to 15 or 20 there was negligible loss of Se and Sp when screening for HIV with 
enzyme-linked immunosorbent assays (ELISA). Additionally, for nucleic acid 
tests (NATs), Kacena et al. (1998a, b) showed negligible loss for Se and Sp as 
group sizes increase when screening for chlamydia and gonorrhea. Of course, the 
assumption of identical Se and Sp values at multiple stages may not hold true if 
different diagnostic tests are used at multiple stages. For example, ELISA tests 
may be used to test the initial groups due to their lower costs and NATs may be 
used to decode positive groups due to their often higher sensitivity values. Also, 
the assumption may not hold true if a positive specimen is diluted enough by 
other specimens within a pool so that the group no longer tests positive. Ideally, 
before implementation of a group testing procedure, an assay should be calibrated 
to make sure this does not happen. If it does happen, there are a few group 
testing procedures that can account for a dilution effect. In particular, McMahan 
et al. (2013) showed that taking into account possible dilution effects can 
improve prevalence estimation.   
1.3 Individual probabilities of positivity 
In many cases where group testing is used, covariate information is available on 
the individual items being screened. This provides extra information that can be 
used to estimate covariate-specific probabilities of positivity for each individual. 
There are two ways these estimates can be obtained in a group testing context. 
First, a binary regression model can be estimated using a training data set of 
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known individual test results. This model can then be applied to the individuals 
being screened through group testing in order to obtain estimates of individual 
probabilities. Second, when a training data set is not available, the individual 
probabilities can be estimated through the methods of Vansteelandt et al. (2000) 
and Xie (2001). These papers discuss how to use initial group responses alone to 
estimate individual probabilities. For the purposes of this dissertation, we solely 
implement the training data approach.   
These individual probabilities of positivity can be exploited in order to reduce 
the number of tests needed for group testing. Hwang (1975) is likely the first 
group testing paper that discusses how to take advantage of probabilities of 
positivity for each individual, and he does so in the context of a Dorfman-like 
procedure. However, this paper did not discuss how these probabilities can be 
estimated or how to incorporate testing error.  
Surprisingly, there was little further group testing research on using individual 
probabilities until recently. Bilder et al. (2010) propose “informative retesting” as 
a way to take advantage of estimated individual probabilities when testing error 
is present. They used individual probability information to improve Sterrett’s 
procedure by retesting individuals with the highest probabilities first within 
positive groups. McMahan et al. (2012a, b) further explored informative retesting 
procedures that looked at how Dorfman’s procedure and array testing could take 
advantage of estimated individual probabilities. Closed form expressions for PSe, 
PSp, PPPV, and PNPV were also derived by McMahan et al. (2012a, b) to assess 
the procedures. They showed that their procedures resulted in similar and 
sometimes even better accuracy than corresponding non-informative retesting 
procedures. Bilder and Tebbs (2012) present an overall comparison of all 
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informative retesting procedures, including those in Chapter 2 of this 
dissertation. They conclude that no single procedure is the overall best in terms 
of the expected number of tests and accuracy. Prevalence, assay accuracy, 
availability of covariate information, the underlying distribution of individual 
probabilities, and application ease can all affect which procedure is best for a 
given situation.  
1.4 Integer programming 
An integer programming (IP) problem is a type of linear or non-linear 
programming (LP) problem where all or part of the solution require integer 
values. IP often uses LP methods to find solutions, but integer programs are 
often more difficult to solve. IP begins by defining an objective function to be 
solved (e.g., minimize a mathematical function) subject to a set of constraints. A 
simple method to find the solution is the simplex algorithm (Dantzig 1963). It 
begins by finding a feasible starting point for the function and then moves from 
one feasible point to another that successively improves the objective function 
(e.g., find a smaller minimum for the objective function). This process continues 
until the optimal solution is found. The direction of movement at each step is the 
direction that improves the function the most, which is often referred to as the 
path of steepest descent (ascent) for minimization (maximization) problems.   
The method of steepest descent (or ascent) is a well-known optimization 
strategy for convex functions. The direction of steepest descent can be found 
using partial derivatives when known. Alternatively, for IP problems, the 
direction is found by calculating the objective function value one step in each 
feasible direction to find the direction with the greatest improvement. Once the 
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direction of steepest descent is found, it can be followed until improvement in 
that direction stops. The process is continued until we reach the optimal solution.  
In the context of this dissertation, the expected number of tests can be treated 
as an objective function for an IP. The method of steepest descent then can be 
used to find how best to split a group into subgroups (the number of subgroups 
and their sizes are integers) to minimize the expected number of tests.  
1.5 Organization of the dissertation 
The remainder of this dissertation is organized as follows. Chapter 2 is the first 
submission of a paper that was published in the Journal of the Royal Statistical 
Society (Series C) (a revision of the paper completed by my advisor was 
published). This paper shows how to use estimated individual probabilities to 
improve the halving group testing procedure. In Section 2.2, we derive formula 
for the mean, variance, and probability mass function (PMF) for the number of 
tests under halving where individuals may have different probabilities of 
positivity. We prove that the mean and variance for individuals from a 
heterogeneous population (individuals have different probabilities of positivity) 
assigned to subgroups at random are the same as assuming homogeneity in the 
population. In Section 2.3, we use the derivations from Section 2.2 to develop a 
new group testing procedure that we name “ordered halving”. We prove that 
ordered halving results in a smaller number of tests than for other 
implementations of halving. In Section 2.4, we examine this reduction in tests in 
the context of a beta distribution assumption for the individual probabilities. In 
Section 2.5, we apply our new procedure to chlamydia and gonorrhea screening in 
Nebraska. Finally, Section 2.6 summarizes the improvements and discusses how 
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other retesting procedures may benefit by taking into account heterogeneity 
among individual probabilities. 
We plan to submit Chapter 3 to the Journal of the Royal Statistical Society 
(Series C) as well. Section 3.2 generalizes the E(T) formula from Section 2.2 for 
any fixed-stage hierarchical group testing procedure. We minimize E(T) by 
finding the optimal configuration through looking at every possible configuration 
(subgroup sizes, members of each group) and using IP methods to find a possible 
solution. In Section 3.3, we examine the performance of our proposals in the 
context of beta distributions. In Section 3.4, we apply our procedures to the 
chlamydia and gonorrhea screening data as described for Section 2.5. Finally, in 
Section 3.5, we summarize our work and discuss future extensions.  
Chapter 4 contains additional items examined during this research that were 
not included in the papers of Chapter 2 and Chapter 3. In Section 4.1, we look at 
conditions when halving will not be optimal and suggest modifications for 
improvement. In Section 4.2, we derive the PMF for the number of tests in a 
general hierarchical group testing procedure. In Section 4.3, we discuss in more 
detail the IP solution used to find possible optimal retesting configurations for 
more than three stages. In Section 4.4, we provide documentation on how to run 
new R functions that implement the research in this dissertation. In Section 4.5, 
we layout possible future research directions. 
Because Chapters 2 and 3 are actual papers, their journal submission formats 
are preserved. For example, references are included within the chapters. 
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Chapter 2: Group testing in heterogeneous 
populations using halving algorithms 
 
Abstract 
Group (pooled) testing is often used to reduce the total number of tests needed 
to screen a large number of individuals for an infectious disease or some other 
binary characteristic. Traditionally, research in group testing has assumed each 
individual is independent with the same risk of positivity. More recently, there is 
a growing set of literature generalizing previous work in group testing to include 
heterogeneous populations so that each individual has a different risk of 
positivity. In this paper, we investigate the impact of acknowledging population 
heterogeneity on a commonly used group testing procedure known as “halving.” 
For this procedure, positive groups are successively split into two equal sized 
halves until all groups test negative or until individual testing occurs. We show 
that heterogeneity does not affect the mean number of tests when individuals are 
randomly assigned to sub-groups. However, when individuals are assigned to sub-
groups based on their risk probabilities, we show that our proposed procedures 
reduce the number of tests by taking advantage of the heterogeneity. This is 
illustrated using chlamydia and gonorrhea screening data from the state of 
Nebraska. 
Key words: binary response; classification; identification; pooled testing; 
retesting; screening. 
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2.1 Introduction 
When a large number of individuals need to be screened for an infectious disease 
or some other binary characteristic, group testing is often used to reduce the 
total number of tests needed. Group testing, also known as pooled testing, refers 
to the process of combining individual specimens (e.g., urine or blood) into a 
“pooled” specimen for testing. If the pool (group) tests negative, all individuals 
within it are declared negative. If the pool tests positive, retesting is needed to 
decode the positive and negative individuals. This idea was introduced by 
Dorfman (1943) as a way to screen World War II soldiers for syphilis. For this 
situation, Dorfman proposed to simply retest all subjects individually within the 
positive groups. Other retesting procedures have been proposed since then, and 
many of them result in a smaller number of tests; see Gupta and Malina (1999) 
and Hughes-Oliver (2006) for a review. The usefulness of group testing has been 
well established in many areas, including blood donation screening (Dodd et al. 
2002), opportunistic testing of individuals for chlamydia (Mund et al. 2008), 
Bovine Viral Diarrhea virus detection in cattle herds (Peck 2006), estimation of 
virus infection levels for carnations (Hepworth, 2009), West Nile virus detection 
among mosquitoes (Biggerstaff 2008), estimating transmission rates of pathogens 
from insects to plants (Tebbs and Bilder 2004), and discovery of chemical 
compounds to use in new drugs (Remlinger et al. 2006).  
Traditionally, research in group testing has assumed each individual to be 
independent with the same risk of positivity p; i.e., a homogeneous population of 
independent individuals with an overall prevalence p. More recently, there is an 
expanding set of literature that generalizes past work to include heterogeneous 
populations. In this setting, each individual has their own individual probability 
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of positivity, and heterogeneity can be modeled using the group testing regression 
methods of Vansteelandt et al. (2000) or Xie (2001). Bilder et al. (2010) show 
further how estimates of these individual probabilities can be used to retest 
individuals in a positive group, and they demonstrate how one can reduce 
significantly the number of tests needed through an extension of Sterrett’s (1957) 
identification procedure.  
Given these advances, it is now important to determine if accounting for 
population heterogeneity provides benefits with other retesting procedures used in 
practice. One widely used procedure involves successively splitting positive 
groups into smaller sub-groups until all positive and negative individuals have 
been identified (Sobel and Groll 1959; Johnson et al. 1991; Pilcher et al. 2005; 
Kim et al. 2007). A common example of this retesting approach is to form sub-
groups which are halves of larger groups; we refer to this as “halving.” Litvak et 
al. (1994) popularized the halving technique in the context of blood donation 
screening for HIV. In our paper, we generalize the use of halving to heterogeneous 
population settings.  
Our work is motivated by chlamydia and gonorrhea screening performed by 
the Nebraska Public Health Laboratory (NPHL). In this setting, clinical, 
demographic, and risk-behavior information is available on each individual being 
screened. Because these risk factors have a strong relationship with whether or 
not an individual has the disease, it is natural to consider the screening 
population as heterogeneous. Through exploiting this heterogeneity, we examine 
how well new halving procedures can reduce the total number of tests needed for 
screening.  
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The paper is ordered as follows. In Section 2.2, we derive the mean, variance, 
and probability mass function for the number of tests under halving. When 
compared to a homogeneous population setting, we prove that the mean and 
variance do not change if individuals from a heterogeneous population are 
assigned to sub-groups at random. Using the derivations from Section 2.2, we 
propose a new halving procedure in Section 2.3 that exploits risk heterogeneity to 
reduce the expected number of tests, and we identify in Section 2.4 the situations 
where our new procedure performs best. In Section 2.5, we apply our new 
procedure to chlamydia and gonorrhea screening in Nebraska. Finally, Section 2.6 
summarizes and discusses how other retesting procedures may benefit by taking 
risk heterogeneity into account.  
2.2 Halving 
2.2.1 Moments for a fixed set of individual risk probabilities 
We begin by assuming that each individual is assigned to exactly one initial 
group. For the remainder of this section and Section 2.3, we focus on one 
particular initial group of size I where individual i has risk probability pi for i = 
1, …, I. Later sections examine individuals across all initial groups.  
Halving involves successively splitting positive groups into two equal sized 
halves. Positive groups are halved until all groups test negative or until 
individual testing occurs. For example, 3-step halving for an initial group of size I 
= 16 begins by testing the entire group. If the group tests positive, the second 
step involves splitting it into two sub-groups of size 8. If either sub-group tests 
positive, a third and final step occurs where each individual in a positive sub-
group is tested. A 4-step halving protocol with I = 16 would continue with 
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halving into groups of size 4 before individual testing. A larger number of steps 
can be performed in a similar manner until only individuals remain.  
We now derive the operating characteristics of halving for a heterogeneous 
group. Let Gs,j = 1 (0) denote a positive (negative) test result for the j
th ordered 
sub-group at the sth step for j = 1, …, 2s-1 and s = 1, …, S. In the last example, 
G1,1 represents the test result for the initial group of size 16, and G2,1 represents 
the test result for the first sub-group of size 8 halved from a positive initial 
group. In a 3-step setting, we can write the expected number of tests for an 
initial group of size I as  
1,1 2,1 1,1 2,1
2,2 1,1 2,2
( | ) 1 2 ( 1) ( 1 1)
( 1 1),
vecE T P G I P G G
I P G G
= + = + = Ç = +
= Ç =
p
 
where T is the number of tests, 1( , ..., ) ,
vec
Ip p ¢=p  and Is,j is the number of 
individuals remaining in the jth ordered sub-group at step s. Adding a fourth step 
leads to an expected number of tests  
1,1 1,1 2,1 1,1 2,2
3,1 1,1 2,1 3,1
3,2 1,1 2,1 3,2
3,3 1,1 2,2 3,3
3,4 1,1 2,2 3,4
( | ) 1 2 ( 1) 2 ( 1 1) 2 ( 1 1)
( 1 1 1)
( 1 1 1)
( 1 1 1)
( 1 1 1).
vecE T P G P G G P G G
I P G G G
I P G G G
I P G G G
I P G G G
= + = + = Ç = + = Ç = +
= Ç = Ç = +
= Ç = Ç = +
= Ç = Ç = +
= Ç = Ç =
p
 
In general for an S-step halving procedure, it follows that  
1
,
2 2
,
{( , ): 1}1 1
( | ) 1 2 { 1}
s
s j
S
vec
s j
s j Gs j
E T P G
--
¢ ¢
¢ ¢ == =
æ ö÷ç= + = +÷å å ç ÷÷çè øp 
2
1,
2
1, ,
{( , ): 1}1
{ 1}
S
S j
S j s j
s j Gj
I P G
-
-
¢ ¢- ¢ ¢ ==
æ ö÷ç = ÷å ç ÷÷çè ø     (2.1) 
for an appropriate number of steps S given the initial group size. When an odd-
sized group is halved, final step group sizes IS,j can be set equal to 0. For 
example, a 4-step halving procedure with I = 7 can have an initial split with sub-
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groups of size 4 and 3. The group of size 3 can be split further into groups of size 
2 and 1. Because the “group” of size 1 cannot be split again, we can set its I4,j 
equal to 0 so that its corresponding term is excluded from the mean calculation. 
Each of the probabilities in the above expressions is found by taking into 
account the true group statuses. Let , 1 (0)s jG =  denote a positive (negative) true 
status for the jth ordered sub-group at the sth step, and define the test sensitivity 
and specificity as , ,( 1 | 1)e s j s jS P G G= = =  and , ,( 0 | 0),p s j s jS P G G= = =  
respectively. The probability that the initial group tests positive can be written 
as   
1,1 1,1 1,1 1,1 1,1
1,1 1,1 1,1 1,1 1,1 1,1
( 1) ( 1 0) ( 1 1)
( 1 | 0) ( 0) ( 1 | 1) ( 1)
P G P G G P G G
P G G P G P G G P G
= = = Ç = + = Ç =
= = = = + = = =
 
   
{ } { }
1 1
(1 ) (1 ) 1 (1 ) ,
I I
p i e i
i i
S p S p
= =
= - - + - -       
where we make the standard assumption that the test outcomes are conditionally 
independent given the true statuses (see Litvak et al. 1994). 
Probabilities involving groups for steps two and higher become more 
complicated to derive because past steps must be taken into account. For 
example, the probability of positivity for the first group at step two, after the 
initial group tests positive, is 
1,1 2,1 1,1 2,1 1,1 2,1
1,1 2,1 1,1 2,1
1,1 2,1 1,1 2,1
( 1 1) ( 1 1 0 0)
( 1 1 1 0)
( 1 1 1 1),
P G G P G G G G
P G G G G
P G G G G
= Ç = = = Ç = Ç = Ç = +
= Ç = Ç = Ç = +
= Ç = Ç = Ç =
 
 
 
 
which takes into account the three ways that 1,1 2,1{ 1} { 1}G G= Ç =  may occur with 
respect to the true statuses. Continuing, we obtain 
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{ }
2,1 2,2
2
1,1 2,1
1
( 1 1) (1 ) (1 )
(1 ) (1 ) 1 (1 )
I
p i
i
e p i i
i B i B
P G G S p
S S p p
=
Î Î
= Ç = = - - +
ì üì üï ïï ïï ïï ï- - - - + í ýí ýï ïï ïï ïï ïî þî þ
2,1
2 1 (1 ) ,e i
i B
S p
Î
ì üï ïï ï- -í ýï ïï ïî þ
       
where ,s ji BÎ  is understood to mean those individuals who belong to the jth 
ordered group at the sth step. These results can be generalized for s> 1 to 
{ }
,
1, 1,
,
{( , ): 1} 1
1
1
{ 1} (1 ) (1 )
(1 ) (1 ) 1 (1 )
s j
a a
I
s
s j p i
s j G i
s
a s a
e p i i
i B i Ba
P G S p
S S p p
+ +
¢ ¢
¢ ¢ = =
- -
Î Î=
æ ö÷ç = = - - +÷ ç ÷÷çè ø
ì üì üï ïï ïï ïï ï- - - - +å  í ýí ýï ïï ïï ïï ïî þî þ 

,
1 (1 ) ,
s j
s
e i
i B
S p
Î
ì üï ïï ï- -í ýï ïï ïî þ
    (2.2) 
where 12s aj - -=  and ,s ji BÎ  denotes the set of individuals within the parent 
group of ,s jB  excluding those in ,s jB  itself (e.g., 3,3i BÎ  denotes all individuals in 
B3,4 because 3,3 3,4 2,2{ } { } { }i B i B i BÎ È Î = Î ). Substituting (2.2) into (2.1), gives 
the expected number of tests for a specific set of risk probabilities. 
To find the variance, we need to calculate the second moment for T. For a 3-
step procedure,  
2 2
1,1 1,1 2,1 2,2
2
2,1 1,1 2,1 2,2
2
2,2 1,1 2,1 2,2
2
1,1 2,1 2,2
( | ) ( 0) 3 ( 0 0 0)
(3 ) ( 0 1 0)
(3 ) ( 0 1 0)
(3 ) ( 0 1 1).
vecE T P G P G G G
I P G G G
I P G G G
I P G G G
= = + = Ç = Ç = +
+ = Ç = Ç = +
+ = Ç = Ç = +
+ = Ç = Ç =
p
 
The four probability terms in this expression are found using Equation (2.2). For 
4-step and higher procedures, the number of terms grows very quickly, so we do 
not recommend direct evaluation. Instead, in Appendix A, we present a recursive 
algorithm to calculate the probability mass function (PMF) of T by exploiting 
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the hierarchical nature inherent to the halving procedure. Combining the PMF 
with the standard variance formula leads to the desired result.  
2.2.2 Treating risk probabilities as random 
Individual risk probabilities will vary from group to group. Therefore, in this sub-
section, we treat these probabilities as random and re-examine our moment 
calculations. Specifically, we now envision pi as independent random variables 
with E(pi) = p for i = 1, …, I. The overall expected number of tests is 
{ }
1
,
2 2
,
{( , ): 1}1 1
( ) ( | )
1 2 { 1}
s
s j
vec
S
s j
s j Gs j
E T E E T
E P G
--
¢ ¢
¢ ¢ == =
=
ì üæ öï ïï ï÷ç= + = +÷å å í ýç ÷÷çï ïè øï ïî þ

p
 
2
1,
2
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{ 1} .
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S j
S j s j
s j Gj
I E P G
-
-
¢ ¢- ¢ ¢ ==
ì üæ öï ïï ï÷ç = ÷å í ýç ÷÷çï ïè øï ïî þ
     (2.3) 
The expectation of the joint probability in (2.1) is 
{ }
,
1, 1,
,
{( , ): 1} 1
1
1
{ 1} (1 ) (1 )
(1 ) (1 ) 1 (1 )
s j
a a
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s
s j p i
s j G i
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E P G S E p
S S E p E p
+ +
¢ ¢
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Î Î=
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,
1 (1 ) .
s j
s
e i
i B
S E p
Î
é ùì üï ïï ïê ú- -í ýê úï ïï ïî þë û
   (2.4) 
Because of independence among the individual probabilities, Equation (2.4) 
simplifies to  
{ }
,
1,1 1, 1, 1, 1,
,
{( , ): 1}
1
1
{ 1}
(1 ) (1 ) (1 ) (1 ) 1 (1 )
s j
a l a l a l a l
s j
s j G
su u l u ls a s a
p e p
a
E P G
S p S S p p+ + + +
¢ ¢
¢ ¢ =
- - --
=
ì üæ öï ïï ï÷ç = ÷í ýç ÷÷çï ïè øï ïî þ
= - - + - - - - +å

 
{ }, ,1 (1 ) ,s j s ju lseS p -- -        (2.5)
 
 
where , , ,1 1
j
s j s i s jil I I== - +å  and , ,1js j s iiu I== å are the lowest and highest 
subscripts, respectively, for the individuals in the sub-group ,s jB  and ,s jl and ,s ju  
are the lowest and highest subscripts, respectively, for the individuals in the sub-
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group ,s jB . The expected number of tests E(T) is found by substituting (2.5) into 
(2.3). 
It is especially insightful to note that 
, ,{( , ): 1}
( { 1})
s j s js j G
P G ¢ ¢¢ ¢ = =  reduces to (2.5) 
when all individuals have a common risk probability p; this implies the 
unconditional means are the same for homogeneous or heterogeneous population 
assumptions. Furthermore, we show in Appendix B that Var(T) also remains 
unchanged. Therefore, when individuals with different risks are assigned 
randomly to groups, neither E(T) nor Var(T) is affected. This is reassuring if the 
researcher is unable to account for heterogeneity when implementing the halving 
procedure.  
An important generalization of these results is that they can be extended to 
other commonly used retesting algorithms, such as Dorfman’s (1943) procedure 
and Sterrett’s (1957) procedure, where moments can also be written in terms of 
(1 )ii p- . This is due to the underlying independence of the risk probabilities. 
For example, Bilder et al. (2010) give the probability mass function for T in a “3-
stage” informative Sterrett procedure. If one treats the individual risk 
probabilities as independent random variables, all of their P(T = t) expressions 
rely on these simple products.  
2.3 Ordered halving 
We have shown that the moment formulas for T do not depend on the individual 
risk probabilities when individuals are assigned to sub-groups at random. Instead 
of random assignment, we now control how individuals are assigned to sub-
groups. Our overall goal is to assign individuals to sub-groups in a manner that 
reduces the expected number of tests.  
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After an initial group of size I tests positive, two sub-groups of equal size are 
created. Our goal is to maximize one sub-group’s probability of testing positive 
and maximize the other sub-group’s probability of testing negative. We show this 
type of sub-group construction allows for faster identification of positive 
individuals on average while allowing negative individuals to be classified sooner. 
Define a set of ordered risk probabilities for an initial group of size I as 
(1) ( )( , , )
ord
Ip p ¢=p   where p(i) denotes the it smallest probability within the 
group. The second step of “ordered halving” creates one sub-group of individuals 
with lower risks 
2,1(1) ( ), , Ip p  and one sub-group of individuals with higher risks 
2,1( 1) ( ), ,I Ip p+  . If one of these sub-groups tests positive and S³ 4 (i.e., individual 
testing does not occur at step 3 for positive sub-groups), the process of halving 
groups by the ordered risks continues in a similar manner.    
 To compare the expected number of tests with and without ordering when 
sub-group sizes are equal, i.e., compare ( | )ordE T p and ( | ),vecE T p  we need only 
focus on  ( )1 ,2 ,{( , ): 1}1 { 1}s s j s js j Gj P G- ¢ ¢¢ ¢ == =å   for each step s = 1, …, S – 1 of 
Equation(2.1). This is true because ordering only changes expressions that are 
functions of the risk probabilities. To help with the comparison, note that 
( )1 ,2 ,{( , ): 1}
1
{ 1}
s
s j s js j G
j
P G
-
¢ ¢¢ ¢ =
=
=å 
{ } 1
,
2
1 1
1 1
2 (1 ) 2 (1 ) (1 ).
a
a j
s
s s s a a s a
e p e e p i
i Ba j
S S S S S p
-
- - - -
Î= =
= + - - - -å å    (2.6) 
When s = 1, Equation (2.6) is the same regardless of whether sub-group 
assignment is ordered or random. However, for any step a> 1, one can show that 
ordering the individual risk probabilities maximizes 1
,
2
1 (1 )
a
a j ii Bj
p
-
Î= -å  . Thus, 
Equation (2.6) is minimized under ordered assignment as long as Se> 1 – Sp, 
which will be true for any diagnostic test used in application. This shows that 
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( | ) ( | )ord vecE T E T£p p  whenever our ordered sub-group construction is used. To 
find E(T) = [ ( | )]ordE E T p , we make use of Equations (2.1) and (2.4) again 
where the individual risk probabilities within (2.4) are properly ordered for the 
sub-groups. Because the expectations in (2.4) are now distribution dependent, a 
simple expression for E(T) no longer exists. However, we can use the result in 
Junjiro (1962) to find the distribution of the ordered risk probabilities. This 
distribution is  
{ }, ,,, , , ,
,
1
( ) ( ) ( ) ( ) ( )
, ,
!
( ,..., ) ( ) ( ) 1 ( ) ,
( 1)!( )!
s j s j
s j
s j s j s j s j
s j
u I ul
l u l i u
i ls j s j
I
f p p F p f p F p
l I u
--
=
ì üï ïï ï= -í ýï ï- - ï ïî þ   
where 
, ,( ) ( )...s j s jl up p£ £  are the ordered risk probabilities for individuals in group 
,s jB  (see Section 2.2.2), f(pi) is the probability density function for pi, and F(pi) is 
the cumulative distribution function for pi. Using this distribution, moments for 
T can be found by substituting the expected values into Equation (2.3). We 
examine values of E(T) for specific distributions in Section 2.4. 
2.4 Mean Comparisons 
Group testing is used in situations where the overall prevalence is small. To 
understand how well ordered halving works in practice, we take p = 0.005, 0.01, 
0.05, and 0.10 and examine the number of tests performed. The distributions 
chosen for pi are a beta(1, 1/p – 1), a uniform(0, 2p), and a degenerate at p 
(which corresponds to a homogeneous population of individuals). We also look at 
an “extreme case” of pi = 1 with probability p and pi = 0 with probability 1 – p. 
While this last case is unrealistic, it is useful to examine because it maximizes the 
variance among the individual probabilities. For all distributions, the expected 
value of pi is p, but the variances are different. For example, the variances are 
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0.048, 0.0023, and 0.0002 for the extreme, beta, and uniform cases when p = 0.05, 
and this ordering among the distributions occurs for the other values of p as well.  
We compare the expected number of tests for these different distributions 
using halving with 2, 3, 4 and 5 steps for a number of different group sizes. To 
make comparisons on a realistic numerical scale, we convert the expected number 
of tests for a single group into the expected number of tests in a population of 
10,000 individuals. We use the equations derived in Sections 2.2.2 and 2.3 to 
calculate the expected number of tests. For the beta distributions, it is necessary 
to estimate the expected values because of the difficulty in integrating over the 
distribution of the order statistics. For the degenerate case, the expected number 
of tests and the variance for the number of tests are calculated using the 
probability mass function algorithm described in Appendix A.  
For each level of overall risk and number of steps considered, Table 2.1gives 
the expected number of tests for a selected number of group sizes. The group 
sizes selected are those that minimize the expected number of tests in the 
degenerate case. For example, the expected number of tests for the degenerate 
case with p = 0.05 is the smallest for two-step halving (Dorfman’s procedure) 
when the group size is 5. It is common for other group sizes to exist where 
ordered halving has a smaller expected number of tests for the same S; thus, the 
expected benefits from ordering will be no worse than those presented here. 
While perfect testing does not often occur in actual applications, we assume Sp = 
Se = 1 because it provides a useful initial examination.  
Table 2.1shows the degenerate case always results in the maximum expected 
number of tests among the four distributions. For 2-step, there is no decrease in 
the expected number of tests from ordered halving; ordering risk probabilities has 
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no advantage when the second step is individual testing. For 3-steps and higher, 
ordered halving always leads to a decrease in the expected number of tests. This 
decrease can be limited for smaller p, but it can be pronounced for larger p. We 
also note that as the variance among the risk probabilities increases, the expected 
number of tests decreases. This result is intuitive because the more diversity in 
information available (in terms of the risk probabilities) the easier it is for an 
“informative retesting” procedure to find positive individuals. Exceptions can 
occur when the last halving step results in uneven group sizes (e.g., 4-step with 
group size of 10 when p = 0.05), because we choose to have the larger risk 
probabilities in the larger sub-group.   
Figure 2.1 plots the expected number of tests when p = 0.05 for a number of 
group sizes and levels of sensitivity and specificity. Additional plots for p = 
0.005, 0.01, and 0.10 are available in Appendix C. Figure 2.1 provides additional 
evidence that ordered halving reduces the expected number of tests, even in the 
presence of imperfect testing. In addition, we see that testing error does not 
change the relative ordering among the distribution cases. Furthermore, the 
group size that results in the smallest number of tests can be larger for ordering 
than for the degenerate case. The meaningfulness of this result may be tempered 
if dilution effects prevent the use of larger group sizes. 
2.5 Application 
The Infertility Prevention Program is a nationally implemented program whose 
goals are to assess and reduce the prevalence of chlamydia and gonorrhea in the 
United States. In Nebraska, urine and swab specimens are collected from 
individuals visiting health clinics throughout the state. These specimens are sent 
then to the Nebraska Public Health Laboratory (NPHL), where each specimen is 
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tested individually for both infections. Clinical, demographic, and risk-behavior 
information is recorded for each individual prior to testing. Therefore, it is 
sensible to envision individuals as having different probabilities of positivity, 
which leads to a potential application of ordered halving.  
To assess how well ordered halving would work in this application, we use 
previously diagnosed individual statuses from the NPHL in the following manner. 
The NPHL’s 2004-year results are used as a training data set to estimate the 
probability of positivity for individuals tested in 2005. First-order logistic 
regression models are fit to the training data with the response variable as disease 
status and the explanatory variables of age, race, clinic type, clinic location, 
reason for visit, symptoms, initial clinical observations, and risk history. These 
models are fit separately by disease (chlamydia and gonorrhea), gender, and 
specimen type (swab or urine). The 2005-year individuals are ordered by 
specimen date and are placed into successive groups by disease/gender/specimen 
combination. Assuming the observed 2005 diagnoses are the true responses, we 
simulate the halving process for each group, where simulated test responses are 
generated with the Se and Sp values provided by the NPHL. We repeat halving 
for each disease/gender/specimen combination ten times to account for 
simulation variability, and we record the average number of tests. 
Table 2.2 displays the average number of tests, and Table 2.3gives the 
percentage reduction in tests for ordered vs. unordered halving at specific group 
sizes. These tables provide the chlamydia screening results only. Similar results 
are found for gonorrhea screening, which are given in Appendix D. Overall, we 
find the chlamydia results to be similar to those found for the beta distribution 
cases in Section 2.4. This is not surprising because a beta distribution often fits 
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these individual probabilities well and overall prevalence ranges from 5.8% to 
13.0% for each gender/specimen combination. Generally, improvements from 
ordering are 1% to 6%, where some improvements are larger for swab/male (up 
to 10.49%). Also, the benefits from ordered halving are more pronounced for 
larger group sizes and prevalences, which is consistent with our findings in 
Section 2.4.  
We have also investigated how well ordered halving performs in terms of 
classification accuracy (e.g., pooling sensitivity, pooling positive predictive 
values). Complete results are in Appendix D. We found no discernible increases 
or decreases through ordered halving.  
2.6 Conclusions 
We have generalized the use of halving algorithms in group testing to 
heterogeneous population settings. Our results demonstrate that ordering risk 
probabilities reduces the number of tests needed to classify all individuals as 
positive or negative. The NPHL example shows a specific instance where ordered 
halving would reduce the testing load. Even when ordered halving provides a 
small percentage reduction in the number of tests, this can be magnified greatly 
in situations with very large numbers of individuals. For example, Kim and 
Hudgens (2009, p. 903) describe a HIV detection program in North Carolina 
where “slight improvements in efficiency can lead to substantial cost savings” 
because 120,000 specimens are screened per year. In addition, the American Red 
Cross screens millions of blood donations for multiple diseases per year by group 
testing (Stramer et al. 2004; Dodd et al. 2002), so even small improvements can 
translate to a large number of tests saved.    
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The reduction in the number of tests through ordering increases as the 
variation in the risk probabilities increases. Also, the test reduction grows as the 
overall prevalence increases. An intuitive explanation for this occurrence comes 
through examining the possible number of tests with halving. For simplicity, 
assume Se = Sp = 1. When there are no positives or only one positive within a 
group at step 1, ordered halving results in the same number of tests as without 
ordering. When there are two or more positives within a group at step 1, ordered 
halving pools the larger probability individuals together. This leads to a larger 
probability that all positive individuals are within one half rather than in both 
halves, which reduces the potential number of tests remaining. Thus, ordered 
halving on a group is beneficial only when there is more than one positive 
individual within the group. This is why ordered halving can have larger optimal 
group sizes.  
Our results from Sections 2.4 and 2.5 lead us to possible future research areas 
that can further improve halving. First, we showed that the variation in the risk 
probabilities was important, but its magnitude of importance changes when 
uneven sub-group sizes are needed. Future research should examine if there are 
optimal unequal sub-group sizes that could be chosen at each step of the group 
splitting process. Variations on this idea include immediate individual testing for 
those individuals with a large positive probability. We see an informal application 
of this already at the Nebraska Veterinary Diagnostic Laboratory; however, 
research is needed to determine actual benefits. Second, group splitting could 
involve more than two sub-groups. For example, Pilcher et al. (2005) use an 
initial group size of 90 and subsequent splits into 9 groups of size 10 when the 
initial group tests positive. It would be of interest to determine how ordering can 
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further reduce the number of tests needed when multiple sub-groups are used. 
Choosing the optimal sub-group sizes and the number of sub-groups for a split 
are open research problems.  
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 Expected number of tests  Max Degenerate 
p Steps Group size  Degenerate Uniform Beta Extreme  difference standard dev 
0.10 2 4  5,938.00 5,938.00 5,938.00 5,938.00  - 95.00 
 3 6  5,938.53 5,880.67 5,827.52 5,577.68  360.86 115.53 
 4 8  6,293.33 6,210.41 6,129.94 5,618.29  674.44 133.33 
 5 16  6,686.70 6,493.23 6,304.65 5,005.09  1,681.61 147.97 
0.05 2 5  4,262.19 4,262.19 4,262.19 4,262.19  - 93.55 
 3 8  3,946.39 3,916.30 3,886.74 3,774.42  171.96 109.92 
 4 10  3,953.15 3,706.77 3,732.70 3,810.91  246.38 119.47 
 5 20  4,094.67 3,781.16 3,739.71 3,403.54  691.13 137.72 
0.01 2 10  1,956.18 1,956.18 1,956.18 1,956.18  - 93.00 
 3 16  1,583.23 1,577.03 1,570.37 1,553.39  29.84 93.01 
 4 20  1,363.43 1,358.51 1,352.43 1,319.42  44.01 83.52 
 5 32  1,257.24 1,250.15 1,241.89 1,171.96  85.29 90.17 
0.005 2 16  1,395.69 1,395.69 1,395.69 1,395.69  - 106.68 
 3 20  1,084.29 1,081.71 1,078.98 1,072.34  11.95 81.19 
 4 32  894.53 891.60 887.60 868.24  26.29 80.47 
 5 48  785.46 782.20 778.08 742.95  42.51 79.13 
Table 2.1. Mean number of tests for specific risk distributions and halving steps where Sp = Se = 1. The group size chosen 
is the optimal size for the degenerate distribution case. Note that two-step halving is Dorfman’s procedure. 
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Group 3-step 4-step 5-step 
Specimen/Gender size Dorfman Unordered Ordered Unordered Ordered Unordered Ordered 
8 1,557.7 1,238.9 1,236.3 1,228.5 1,207.8 NA NA 
12 1,735.1 1,297.5 1,229.1 1,136.2 1,104.8 NA NA 
Urine/Female 16 1,925.6 1,405.6 1,352.0 1,146.4 1,102.5 1,132.2 1,100.8 
24 2,114.5 1,540.3 1,502.8 1,161.3 1,115.4 1,018.4 1,019.7 
32 2,186.5 1,632.1 1,541.3 1,211.9 1,085.4 1,007.1 961.3 
8 2,415.6 2,009.0 1,971.8 1,996.4 1,965.2 NA NA 
12 2,701.8 2,109.2 2,076.8 1,908.0 1,884.2 NA NA 
Urine/Male 16 3,037.4 2,338.2 2,253.2 2,000.0 1,930.6 1,992.9 1,946.8 
24 3,277.4 2,598.4 2,519.2 2,092.5 2,022.0 1,935.3 1,857.6 
32 3,506.6 2,882.0 2,762.4 2,233.8 2,236.2 1,930.7 1,909.9 
8 9,492.6 7,833.0 7,705.8 7,804.2 7,731.2 NA NA 
12 10,791.9 8,222.9 8,007.2 7,443.4 7,242.8 NA NA 
Swab/Female 16 12,341.1 9,035.2 8,759.5 7,569.4 7,404.9 7,533.7 7,387.7 
24 14,481.7 10,448.6 9,957.0 8,115.7 7,745.4 7,368.4 7,107.1 
32 15,691.0 11,711.6 11,124.1 8,771.6 8,173.4 7,378.6 7,103.1 
8 2,984.6 2,633.8 2,534.6 2,721.6 2,639.0 NA NA 
12 3,357.8 2,840.0 2,680.4 2,666.1 2,546.3 NA NA 
Swab/Male 16 3,568.0 2,996.4 2,815.6 2,638.4 2,495.4 2,702.4 2,579.2 
24 3,819.0 3,325.0 2,998.6 2,832.2 2,607.4 2,616.2 2,471.8 
32 3,802.6 3,427.5 3,165.1 2,939.8 2,631.3 2,605.9 2,403.6 
Table 2.2. Average number of tests for chlamydia screening. For urine/female, there are 2,679 individuals, Se = 0.805, and 
Sp = 0.96. For urine/male, there are 3,852 individuals, Se = 0.930, and Sp = 0.95. For swab/female, there are 19,451 
individuals, Se = 0.928, and Sp = 0.96. For swab/male, there are 4,085 individuals, Se = 0.925, and Sp = 0.95.
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Group 
 
Percentage decrease 
Specimen/Gender size 
 
3-step 
 
4-step 
 
5-step 
 
8 
 
0.21% 
 
1.68% 
 
NA 
 
12 
 
5.27% 
 
2.76% 
 
NA 
Urine/Female 16 
 
3.81% 
 
3.83% 
 
2.77% 
 
24 
 
2.43% 
 
3.95% 
 
-0.13% 
 
32 
 
5.56% 
 
10.44% 
 
4.55% 
 
8 
 
1.85% 
 
1.56% 
 
NA 
 
12 
 
1.54% 
 
1.25% 
 
NA 
Urine/Male 16 
 
3.64% 
 
3.47% 
 
2.31% 
 
24 
 
3.05% 
 
3.37% 
 
4.01% 
 
32 
 
4.15% 
 
-0.11% 
 
1.08% 
 
8 
 
1.62% 
 
0.94% 
 
NA 
 
12 
 
2.62% 
 
2.70% 
 
NA 
Swab/Female 16 
 
3.05% 
 
2.17% 
 
1.94% 
 
24 
 
4.70% 
 
4.56% 
 
3.55% 
 
32 
 
5.02% 
 
6.82% 
 
3.73% 
 
8 
 
3.77% 
 
3.03% 
 
NA 
 
12 
 
5.62% 
 
4.49% 
 
NA 
Swab/Male 16 
 
6.03% 
 
5.42% 
 
4.56% 
 
24 
 
9.82% 
 
7.94% 
 
5.52% 
 
32 
 
7.66% 
 
10.49% 
 
7.76% 
Table 2.3. Percentage reduction in tests for ordered vs. unordered halving at a 
specific number of steps and group size.
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Figure 2.1. Mean number of tests when p = 0.05. Each row of panels corresponds to the number of halving steps. Each 
column of panels corresponds to specificity and sensitivity settings. 
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Chapter 3: Optimal retesting configurations for 
hierarchical group testing 
 
Abstract 
Hierarchical group testing is a widely implemented procedure used to efficiently screen 
individuals for infectious diseases and other binary characteristics. This screening 
protocol works by amalgamating individual specimens into groups for testing. Groups 
testing positive are successively divided into smaller subgroups and retested to decode 
positive individuals from negative individuals. In our paper, we propose a general 
procedure to incorporate risk factor information into the testing process by optimally 
selecting these subgroup configurations for the individuals. We derive the expected 
number of tests and classification accuracy measures for our proposals, and we show 
that our proposals can significantly reduce the number of tests needed and still maintain 
high classification accuracy. An added benefit is that our proposals can be much more 
easily applied than most other group testing procedures that take into account risk 
factor information. We apply our proposals to infectious disease screening which was 
performed as part of the Infertility Prevention Project in the United States.  
Key words: classification; Infertility Prevention Project; informative retesting; pooled 
testing; retesting; screening  
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3.1 Introduction 
Infectious disease screening frequently occurs through the process known concurrently as 
group testing and pooled testing. For this screening protocol, clinical specimens (e.g., 
blood, urine) from separate individuals are amalgamated into a single specimen. 
Individuals within negative testing groups are declared negative. Individuals within 
positive testing groups are retested in some predetermined manner to decode the 
positive individuals from the negative individuals. As long as group sizes are judiciously 
chosen and the overall disease prevalence is small, group testing significantly reduces the 
overall number of tests required while subsequently reducing costs. Due to these benefits 
and the high volume of clinical specimens that often occur for infectious disease 
screening, group testing is successfully being applied now for chlamydia and gonorrhea 
testing within the Infertility Prevention Project (Lewis et al. 2012); for HIV, hepatitis 
B, and hepatitis C screening of blood donations (American Red Cross 2013; Hourfar et 
al. 2008); and for HIV screening among known HIV-positive individuals to detect 
antiretroviral treatment failure (Tilghman et al. 2011, Smith et al. 2009; Mehta et al. 
2011). 
Group testing algorithms are generally divided into two categories: hierarchical and 
non-hierarchical. Hierarchical group testing involves dividing positive groups into two or 
more non-overlapping groups for retesting, where a group size may be as small as one. If 
any of these subsequent groupings test positive, additional stages of dividing occur until 
individual testing at the final possible stage S, where individuals are decoded as positive 
or negative. Throughout the process, the results from a previous stage are necessary 
before further retesting can be performed. In contrast, non-hierarchical group testing 
involves placing individuals into overlapping groups in the hope that positive testing 
groups quickly lead to the identification of positive individuals. In particular, two-
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dimensional array (matrix) testing places specimens into an array where specimens 
within rows and columns are pooled. The intersections of positive testing groups 
correspond to those individuals who are potentially positive; additional individual 
retests can be completed within these intersections as necessary. For a further review of 
hierarchical and non-hierarchical group testing, see the excellent chapter given by 
Hughes-Oliver (2006). 
Our paper focuses on hierarchical group testing by taking advantage of recent 
advances in group testing collectively known as “informative retesting” (Bilder et al. 
2010, McMahan et al. 2012a, McMahan et al. 2012b, Black et al. 2012). Informative 
retesting incorporates individual probabilities of positivity into the decoding process. To 
obtain these probabilities, binary regression models are estimated using individual 
disease statuses along with individual risk factor covariates from a training data set. 
Individual probabilities of positivity are estimated with these models and used for 
retesting. By taking advantage of the heterogeneity among these probabilities, we 
propose in our paper new informative retesting procedures that significantly reduce the 
number of tests needed while also being easier to apply than most previously proposed 
methods. We achieve our gains in testing efficiency by optimally selecting the number of 
subgroups and their sizes at each stage. We achieve our ease in application by limiting 
the number of testing stages and ordering individuals by their probability of positivity.  
While our methods can be applied to a large number of infectious disease settings, we 
focus our discussion on the high volume of clinical specimens evaluated each year for the 
Infertility Prevention Project (IPP). The IPP was a nationally implemented program in 
the United States for chlamydia and gonorrhea detection, and hundreds of thousands of 
specimens are screened each year at laboratories across the country. Due to this high 
volume, many states (e.g., Idaho, Iowa, New York, Oregon, Virginia, Washington, and 
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Wisconsin) now use group testing for their screening, and it is likely that many more 
states will need to in the future given the current fiscal environment. With each 
specimen tested, risk factors, such as gender, sexual history, and clinician observations, 
are available. This has prompted at least one state, Idaho, to implement the “threshold 
optimal Dorfman” informative retesting procedure of McMahan et al. (2012a), which 
takes advantage of known risk factors to reduce their number of tests (Lewis et al. 
2012). It is of interest to determine if further reductions in tests can be obtained by 
taking advantage of this risk factor information. We will show later that this is the case, 
which in turn leads to lower screening costs.  
An outline of our paper is as follows. In Section 3.2, we derive the expected number 
of tests and measures of classification accuracy for hierarchical group testing. Using 
these derivations, we develop new proposals that reduce the number of tests needed to 
decode positive from negative individuals within positive testing groups. In Section 3.3, 
we compare our proposals through the use of beta distributions. In Section 3.4, we apply 
our procedures to chlamydia and gonorrhea screening data from the IPP. Finally, in 
Section 3.5, we summarize our work and discuss future extensions.  
3.2 Hierarchical group testing 
3.2.1 Expected number of tests 
Consider a group of I individuals that are to be screened for an infectious disease using 
group testing. Define Gsj as a binary random variable denoting the test status for a 
group (or subgroup) j at the sth stage, where a 0 denotes a negative test result and a 1 
denotes a positive test result. For example, G11 denotes the initial group’s test outcome. 
The number of individuals screened within the group corresponding to Gsj is defined as 
Isj, where I11 ºI. If Gsj = 0, all individuals within the corresponding group are declared 
negative. If Gsj = 1, individuals within the corresponding group are divided into msj 
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subgroups for the next stage of testing. Define cs as the total possible subgroups tested 
at stage s, where c1 = 1 and 1 1,1s
c
s s jjc m- -== å  for s = 2, …, S. 
To help explain this notation, consider the use of three-stage hierarchical group 
testing implemented by Pilcher et al. (2005) to screen blood donations. Specimens from 
blood donations were placed into groups of size I = 90. If G11 = 0, all individuals are 
diagnosed as negatives. If G11 = 1, the initial group is divided into m11 = 9 subgroups of 
size I21 =  = I29 = 10 for stage 2 testing. For any of the subgroups at stage 2 that test 
negative, i.e., G2j= 0, these corresponding individuals are declared negative. If G2j = 1 
for a particular subgroup, it is divided into m2j = 10 subgroups of size one. Notice that 
the total number of possible subgroups tested at stage 3 is c3 = 90 because individual 
testing would occur. We provide additional examples of more complicated testing 
protocols in Appendix E.  
The expected number of tests for the group of I individuals is 
1
{( ): 1}1 1
( ) 1 { 1}
s
sj
cS
sj s j
s j Gs j
E T m P G
-
¢ ¢
¢ ¢ == =
æ ö÷ç= + = ÷å å ç ÷÷çè ø      (3.1) 
over S stages. We see that E(T) depends on the number of subgroups, subgroup sizes, 
and probabilities of groups testing positive. The probability expression within Equation 
(3.1) is a joint probability representing a succession of groups testing positive up to and 
including 1sjG = . For example, to find E(T) for the Pilcher et al. (2005) application, 
one probability that would be needed is   
21
11 21
{( ): 1}
{ 1} ( 1 1)s j
s j G
P G P G G¢ ¢
¢ ¢ =
æ ö÷ç = = = Ç =÷ç ÷çè ø  
when s = 2 and j = 1.  
To find the general probability expression within Equation (3.1), we need to 
reexpress it as a function of the true group statuses sjG  to account for testing error that 
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can occur during screening. Define ( 1 | 1)e sj sjS P G G= = = and ( 0 | 0)p sj sjS P G G= = =  
as the sensitivity and specificity, respectively, of the assay. The joint probability is then 
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   (3.2) 
where pi is the probability that individual i is truly positive, sji BÎ is understood to 
mean those individuals who belong to the jth ordered group at the sth stage, and sji BÎ  
denotes the set of individuals within the parent group of sjB  excluding those in sjB  
itself. Equation (3.2) is written the same way as the expected number of tests formulas 
given in Black et al. (2012), which examined the special case of hierarchical group 
testing where positive groups are halved. This equivalence is simply due to the 
generality of the sjB  and sjB  notation, and the derivation of E(T) is the same. We can 
now use Equation (3.2) in Equation (3.1) to fully define E(T). 
3.2.2 Optimal retesting configurations 
For infectious disease screening settings, we want the number of tests to be as small as 
possible while also minimizing the number of stages. As a result, costs generally will be 
as low as possible and testing will be completed in a timely manner. Before an 
application of group testing begins, we will not necessarily know the best retesting 
configuration (i.e., group sizes, members of each group, …) for positive testing groups. 
However, we can examine the expected number of tests among potential configurations 
before screening in order to choose one that is “optimal”; i.e., choose the procedure that 
minimizes the expected number of tests.  
To find the best retesting configuration, we first order individuals by their 
probability of positivity within an initial group that tests positive.  This helps to isolate 
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those individuals with small and large probabilities while also lowering the number of 
possible configurations that need to be examined (to be discussed more shortly). Define 
p(i) for i = 1, …, I as these ordered individual probabilities, where p(i)£p(i+1). Whenever a 
group tests positive, we assume that individuals are put into groups successively by this 
ordering. For example, a group of size I = 6 could be divided into m11 = 3 groups of size 
I21 = 3, I22 = 2, and I23 = 1. This retesting configuration will contain the corresponding 
individuals with the following probabilities: subgroup #1 includes p(1), p(2), p(3), subgroup 
#2 includes p(4), p(5), and subgroup #3 includes p(6). Ordering in this manner is intuitive 
because it allows larger (smaller) subgroups to be formed among the low-probability 
(high-probability) individuals, which in turn leads to reductions in the number of tests 
needed for decoding. We define the optimal retesting configuration (ORC) as the 
configuration which minimizes E(T) when the ordered individuals are successively put 
into subgroups of this form.  
3.2.3 All possible configurations 
The most direct approach to find the ORC is to calculate E(T) for all possible 
configurations. For a three-stage procedure, it is easy to see that the number of 
configurations is the combination 1 1I C-  when two subgroups are formed at stage 2, 
1 2I C-  when three subgroups are formed at stage 2, and so on. In general, there are 
11
10 2
II
I ii C
--
-= =å  configurations for a three-stage procedure. For example, for an initial 
group of size I = 4, this leads to 24-1 = 8 possible configurations of subgroups at stage 2 
with sizes: [4], [3,1], [2,2], [1,3], [2,1,1], [1,2,1], [1,1,2] or [1,1,1,1], where we use [⋅] to 
denote each possible subgroup configuration of particular sizes. If needed, a third stage 
for positive testing subgroups of size two or more leads to individual testing. Note that 
this enumeration contains configurations that would not typically be implemented, such 
as [4] (retest the entire group again), and those that would not result in a stage 3, such 
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as [1,1,1,1] (further individual testing would not be needed). Similarly, one can show the 
number of subgroups for a four-stage procedure to be  
2
2
2 2 3 2
2 3 2
11 1
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1 1 1
0 0 0
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c I
I c c c I c
c c c
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For a 5-stage procedure, we have 14I-  possible configurations. This pattern can be 
continued using binomial expansion, so that S stages have 1( 1)IS --  possible 
configurations.  
The number of retesting configurations grows exponentially. With respect to 
calculation time for E(T), consider the case of I = 12. A three-stage procedure results in 
2,048 configurations. Using R 2.15.0 (R Development Core Team, 2013) and a single 
2.40 GHZ core of a processor, the enumeration process takes less than one second. A 
four-stage procedure leads to 177,147 configurations that takes approximately 2.4 
minutes to complete, and a five-stage procedure leads to 4,194,304 configurations that 
takes over one hour to complete. For at least up to four-stages, time is not too much of 
a concern. The five-stage configuration may be reasonable in some applications as long 
as it does not need to be repeated multiple times (see Section 3.4 for application 
examples). Furthermore, the enumeration of these configurations falls into a setting 
commonly known as “embarrassingly parallel”, so additional time savings could be 
obtained by parallelizing the computations. Once E(T) is found for each configuration, 
the optimal configuration is the one with the minimum expected value.  
It is important to note that we have limited the possible configurations to those 
constructed sequentially with ordered individual probabilities. In addition to it being an 
intuitive approach, past research has shown that ordering is a preferred choice. For 
example, Black et al (2012) proved that for the special case of dividing a group into 
only two subgroups at each stage, ordering always produced an E(T) as small as or 
smaller than unordered. McMahan et al. (2012a) also uses this methodology in his 
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application of a two-stage procedure. Finally, again for the case of a two-stage 
procedure, Hwang (1975) showed that groups with a larger number of individuals should 
always have smaller individual probabilities than groups with a fewer number of 
individuals. 
3.2.4 Steepest descent search algorithm 
For many applications, the maximum possible initial group size cannot be large due to 
the possibility of dilution effects. However, there are other applications where large 
initial group sizes can be used. For example, we discussed earlier the use of a three-stage 
procedure by Pilcher et al. (2005) where an initial group size of 90 is used. Other 
applications include Quinn et al. (2000) where a four-stage procedure is used with an 
initial group size of 100, subgroup sizes of 50 at stage 2, and subgroup sizes of 10 at 
stage 3 before individual testing at stage 4. When there are large group sizes, examining 
all possible configurations may not be computationally feasible without massively 
parallel computations performed by supercomputers. For these larger initial group size 
scenarios, we formulate the problem as an integer program and use the method of 
steepest descent to more quickly find a retesting configuration that we refer to as the 
candidate retesting configuration (CRC). Note that in most cases it will be the same as 
the ORC or lead to an expected number of tests very close to that of the ORC.  
The method of steepest descent begins by first choosing a base configuration for a 
specified number of subgroups at each stage. We alter this base configuration by adding 
one member to a subgroup and subtracting one member from a different subgroup for 
each subgroup pair. We then choose a “better” retesting configuration that has the 
lowest E(T) among the new ones created. We continue this same process, where the 
number of subgroups at each stage stays the same until no other configurations can be 
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found with a lower E(T). We repeat this process for all other possible number of 
subgroups. The configuration that minimizes E(T) overall is the CRC.  
For example, consider an initial group of size 16 to be decoded over three stages 
where a base configuration at stage 2 is chosen to be [8,4,4]. We then compare E(T) for 
that configuration to the expected number of tests for [9,4,3], [9,3,4], [8,3,5], [8,5,3], 
[7,5,4] and [7,4,5]. If [8,4,4] had the smallest E(T) among these configurations, the 
process would stop. Otherwise, we choose the configuration with the smallest E(T) and 
make this our new base configuration. We continue to perform the same add one and 
subtract one process to determine if there is a configuration with a smaller E(T). The 
search algorithm ends when the base configuration has the smallest E(T) within the 
constraints of the algorithm. In addition to three subgroups, the same process would be 
used for 2, 4, 5, …, 16 subgroups in order to find the CRC. For more stages, we would 
simultaneously change sizes of the subgroups at each stage.  
There are a number of ways to choose the base configuration for the algorithm. For a 
three-stage procedure with initial group size of I and m11 subgroups to be formed from 
it, we arrange specimens at stage 2 so that the I – m11 + 1 individuals with the smallest 
probabilities are in the first subgroup. The remaining m11 – 1 subgroups each have one 
individual. We use base configurations of this type because subgroups should get smaller 
as individual probabilities increase. However, this base configuration structure, and the 
method of steepest descent overall, does not guarantee that the CRC found will 
minimize E(T) overall unless there is upward convexity in E(T) as a function of the 
number of subgroups and their sizes. In Appendix F, we give special cases where 
convexity fails. Despite the absence of convexity in general, we show in Sections 3.3 and 
3.4 that the CRC does result in an E(T) which is the same or very close to that 
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resulting from the ORC. Therefore, the CRC still provides a convenient alternative to 
the ORC when all possible configurations cannot be easily enumerated.  
3.2.5 Accuracy measures 
While the expected number of tests is of primary interest when evaluating a group 
testing procedure, the accuracy of correctly classifying truly positive and negative 
individuals is of great interest as well. Define Yi = 1(0) as the positive (negative) 
diagnosed status of the ith individual (i = 1, …, I), and define 1(0)iY = in a similar 
manner as the true status. The probability of a correct positive diagnosis, the pooling 
sensitivity, is ( ) ( 1 | 1)ie i iPS P Y Y= = = for individual i. Similarly, the pooling specificity 
is ( ) ( 0 | 0)ip i iPS P Y Y= = =  for a correct negative diagnosis of individual i. We can also 
define the pooling positive predictive value and the pooling negative predictive value for 
individual i as ( ) ( 1 | 1)i i iPPPV P Y Y= = =  and ( ) ( 0 | 0),i i iPNPV P Y Y= = =  
respectively. These predictive values are useful accuracy measures once a diagnosis is 
made.   
For the ith individual to be diagnosed as positive ( 1iY = ), the initial group and all 
subsequent sub-groups containing the individual, including the last sub-group which 
contains only the ith individual, need to test positive as well. Define subgroup j in stage 
L (L£S) as the last subgroup and stage where individual i could be tested. The 
individual pooling sensitivity is then   
( )
{( ): 1} {( ): 1}
( 1 | 1) { 1} { 1}
Lj Lj
i L
e i i s j s j e
s j G s j G
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where we use the assumption that test results are conditionally independent once the 
true status is known (see Litvak et al. 1994 for justification of this assumption). Thus, 
the pooling sensitivity is the same for each individual testing positive within L stages. 
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Note that this result is practically the same as given by Kim et al. (2007), where it was 
assumed that all individual probabilities of positivity were equal (p1 =  = pI).      
The remaining accuracy measures are found in a similar manner. The individual 
pooling specificity can be expressed as  
( )
{( ): 1}
1 ( 1 | 0)
1 ( 1) ( 1 1) ( 0)
1 ( 1) ( 1 | 1) ( 1) ( 0)
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where 
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 is found from Equation (3.2). Notice that the individual 
pooling specificity is a function of the individual probabilities unlike what was found for 
( )i
ePS . The predictive values are then found through applications of Bayes’ rule: 
( )
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Again, we see these measures differ as functions of the individual probabilities.   
To find overall measures of accuracy for all individuals screened, we need to modify 
our notation to designate a particular group for an individual. Define Yik and ikY  as 
before, but now for individual i in group k, where i = 1, …, Ik and k = 1, …, K. In a 
similar manner, we add a k to the individual pooling sensitivity ( )ikePS , the individual 
pooling specificity ( )ikpPS , and the individual probability of positivity ( 1)ik ikP Y p= =  
notation. Overall measures of pooling sensitivity and specificity across all individuals 
screened are 
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and 
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Overall measures of the predictive values are  
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These expressions for the accuracy measures are logical extensions to those given in 
Altman and Bland (1994a, 1994b). 
3.3 Mean and accuracy comparisons 
In actual application, we would estimate the individual probabilities pi. These estimates 
would then be used to develop the ORC or CRC and to assess overall measures of 
accuracy. In order to understand properties of our proposals first, it is useful to assume 
a particular probability distribution for pi and examine how well our proposals work 
under specific situations. In particular, we use a beta distribution for pi here because its 
support is between 0 and 1 and the distribution is flexible enough to emulate actual 
group testing applications.  
Let pi ~ beta(a, a(1 – p)/p) for i = 1, …, I, where E(pi) = p and Var(pi) = p2(1 – 
p)/(a + p). For specific values of a and p, we will examine the expected performance of 
our proposed group testing procedures. Note that p represents the overall prevalence for 
a population. Also, notice that as a  ¥, the variance approaches 0 so that individual 
probabilities become homogeneous (pi = p for i = 1, …, I). Conversely, as a  0, the 
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variance grows, which induces more heterogeneity among the individual probabilities. In 
fact, one can show that the limiting distribution is Bernoulli with mean p (McMahan et 
al. 2012b); thus, pi = 1 with probability p and pi = 0 with probability 1 – p. While this 
is unlikely to occur in application, it is useful to consider this situation because it 
maximizes the amount of heterogeneity within a group. We also choose additional 
values of a and p for our investigations that are motivated by the IPP data example of 
Section 3.4 (where maximum likelihood estimates are given in Table 3.1). For a given 
group size I, we calculate E(p(i)), the expected value of an ordered individual 
probability, based on an a and p combination. We find the ORC and CRC using these 
expected values in place of their corresponding pi to examine the corresponding expected 
number of tests and accuracy measures. We provide an example of a CRC for I = 18, p 
= 0.05, and a = 1 in Appendix E. 
We limit our subsequent investigations by the following. First, only three- and four-
stage procedures are examined because a larger number of stages can be more difficult 
to implement in practice, while also resulting in low pooling sensitivity. Second, only 
groups of size 20 or less are used due to possible dilution effects in some applications 
and because of computational limitations. Finally, only results involving CRC are 
presented, because it found the same configuration as did the ORC in all three-stage 
cases and all four-stage cases with I≤ 14. For four-stage and I> 14, we did not compute 
the ORC due to excessive computation time.  
Figure 3.1plots E(T)/I, the expected number of tests per individual, for Se = Sp = 
0.95. Appendix G lists the numerical values for E(T)/I along with Isj, the group sizes at 
each stage. As one would expect, Figure 3.1shows that a four-stage procedure has a 
smaller expected number of tests than a three-stage procedure for the same a and p, 
except when probabilities are homogeneous and p is large or the group size is small. Of 
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course, four-stage can be more difficult to apply. Also, we see that as the variability 
among the pi values increases (a decreases), the expected number of tests decrease. This 
occurs because the retesting procedure can more adeptly take advantage of the 
information provided by the differences in probabilities as their spread increases. For 
example, in an extreme situation of Se = Sp = 1 for the maximum heterogeneity case, 
each individual with pi = 1 would be retested individually in subgroups of size 1 and 
each pi = 0 would be retested in one subgroup, which perfectly optimizes the testing 
strategy.   
Figure 3.2plots the overall accuracy measures for p = 0.05 with Se = Sp = 0.95. We 
have included similar plots in Appendix H for p = 0.01, 0.10, and 0.15. Overall, as 
probabilities become more heterogeneous, the diagnostic values increase. This shows an 
important benefit gained by taking advantage of heterogeneity among the individual 
probabilities. At the same levels of heterogeneity (same levels of a), we see that PSp and 
PPPV are larger for four-stages than for three-stages, while the reverse is generally true 
for PSe and PNPV. The reason for the PSp and PPPV result is that positive diagnoses 
occur only after multiple positive tests. Thus, a more stringent criterion is needed to be 
diagnosed as a positive with four-stages. Conversely, PSe and PNPV tend to be larger 
for three-stages because it takes only one negative test to produce a negative diagnosis 
for an individual. Note for the homogeneous case, PSe = 
S
eS  almost everywhere except in 
situations where subgroups contain single individuals before stage S.   
3.4 Infertility Prevention Project 
To assess how well ORC or CRC work in application, we examine a database of 
previously diagnosed individuals who were tested for the IPP. Our focus is on the tests 
performed in the state of Nebraska because they currently perform individual testing for 
their chlamydia and gonorrhea screening. This type of data, rather than group testing 
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data from other states, provides a clearer assessment because fewer assumptions need to 
be made through its use.  
3.4.1 Background and methods of application 
For each individual tested in Nebraska, information is available on clinical observations 
(any symptoms, cervical friability, pelvic inflammatory disease, cervicitis, and 
urethritis), demographic variables (age, race), and risk behavior (multiple partners, new 
partner in the last 90 days, contact with an individual who has a sexually transmitted 
disease). We treat these items as covariates (all are binary except for age) in a logistic 
regression model to estimate the individual probability of disease positivity. The 
observed disease diagnoses are treated as the true responses in fitting these models, so 
that we can assess the accuracy of our proposals. Separate models are found for each 
disease (chlamydia or gonorrhea), gender (male or female), and specimen type (urine or 
swab) combination. We estimate the models based on data from 23,146 individuals who 
were tested in 2008. These models are then applied to the 27,521 individuals tested in 
2009 to obtain individual estimates of positivity, where Table 3.1summarizes these 
individuals by disease, gender, and specimen type combination. We apply our group 
testing proposals to these data from 2009. 
In most applications, individuals would be placed into an initial group based on the 
order in which the testing laboratory received the specimen. We replicate the process 
here by placing individuals into groups in this same manner. Let Tk denote the number 
of tests needed to diagnoses individuals in the kth group of size Ik. For K groups, our goal 
is to estimate the expected number of tests for the 2009 data using  
1
1
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where we have added a subscript k in the appropriate locations to denote the initial 
group number, similarly to what was done in Section 3.2.5. We calculate 
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 by replacing ip  with iˆkp , which is the individual estimate of 
disease positivity given by our logistic regression model, in Equation (3.2). 
In practice, there are two ways that an ORC or CRC can be found for a group. First, 
we can find a retesting configuration separately for each positive testing initial group 
through the use of the available estimated individual probabilities. Thus, we adaptively 
choose a retesting configuration using the actual individuals within a group, so we refer 
to this as an “adaptive” procedure (A-ORC, A-CRC). Second, a simpler method is to 
estimate one overall “best” retesting configuration using a training data set (the 2008 
data here) and apply it to each positive testing initial group in 2009. We implement this 
approach by first finding (1)ˆ kp , …, ( )ˆ I kp , where the subscript “(i)k” allows us to denote 
ordered probabilities within group k, for all possible groups of size I≤ 20 in the 2008 
data. We average these probabilities across the initial groups to form (1)pˆ , …, ( )ˆ Ip , and 
we find one retesting configuration with these probabilities. Because only one 
configuration is applied throughout 2009, we refer to this as a “non-adaptive” procedure 
(N-ORC, N-CRC). In the results that follow, we signify the maximum number of 
possible stages used by appending S to the end of the method, e.g., three-stage non-
adaptive ORC would be N-ORC3. 
3.4.2 Results 
Tables 3.2 and 3.3provide summaries of our results. Note that we did not include N-
ORC4 due to the excessive time it would take to complete its calculations. We have 
included additional results from a homogeneous probability assumption, where we find 
the ORC assuming equal probabilities (denoted by H3 for three-stage and H4 for four-
stage in the tables), and from using ordered halving (Black et al. 2012) (denoted by 
OH3 for three-stage and OH4 for four-stage in the tables) for comparison purposes. For 
each procedure, we choose the optimal initial group size by minimizing the expected 
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number of tests in the 2008 data for group sizes 5 to 20 and then apply the resulting 
initial group size to the 2009 data. 
Overall, N-CRC4 generally results in the smallest number of tests, where the 
reduction can be by as much as 30.6% when compared to H3 and 30.0% when compared 
to H4. Among the three-stage procedures, N-CRC3 and A-CRC3 always result in 
significant reductions in tests in comparison to H3 (up to 23.1%). Interestingly, while A-
ORC3 is always less than N-ORC3, it is only by small amounts (the largest amount is 
3.33%), which indicates that the much easier to implement non-adaptive approach that 
implements the CRC is likely to be preferred for actual application. Also, comparing N-
ORC3 to N-CRC3 and A-ORC3 to A-CRC3, the biggest difference is 0.09%, so the 
CRC may be preferred to the ORC when the ORC takes an excessive time to compute. 
With respect to accuracy, four-stage procedures are less accurate with respect to the 
PSe and PNPV than three-stage procedures, and vice versa for the PSp and PPPV, as 
would be expected. When compared based on the same number of stages, the ORC and 
CRC procedures have similar levels of accuracy to the H3 and H4 procedures, where one 
procedure does not necessarily always have a larger or smaller accuracy. Also, the 
accuracy levels for the adaptive and non-adaptive approaches are similar.  
Similar to Section 3.3, the greatest benefits to using the ORC or CRC occur when 
there is the most variability among the estimated individual probabilities. Table 
3.1gives the variances by disease/gender/specimen combination. With respect to 
chlamydia, the male/swab combination has the largest variability and tends to have the 
largest reductions in ˆ( )E T+ . With respect to gonorrhea, male/swab again has the largest 
variability and it has the largest or second largest reductions in ˆ( )E T+ .  
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3.5 Discussion 
In our paper, we show that finding the ORC or CRC can significantly reduce the 
expected number of tests during the decoding of positives from negatives, while also 
maintaining classification accuracy. We also show two ways that our proposals can be 
implemented, where the more easily applied non-adaptive approach achieved similar 
results to the more difficult to implement adaptive approach. This is especially 
important because implementation of the non-adaptive approach would allow 
practitioners to use only one retesting configuration throughout the screening process. 
Finding an ORC over three stages is closely related to the pool-specific optimal 
Dorfman (PSOD) procedure proposed by McMahan et al. (2012a). In summary, PSOD 
is a two-stage procedure that tries to minimize the expected number of tests using a 
greedy search algorithm to place N individuals within an initial set of groups, where 
each individual has a different probability of positivity. The groups are tested, and 
positive testing groups are decoded through individual testing. If we let N = I as in 
Section 3.2, we see that PSOD is very similar to the last two stages of our three-stage 
ORC procedure. The advantage that ORC has over PSOD is ORC’s first stage can 
immediately diagnosis all I individuals as negative if the initial group tests negative. If 
the initial group tests positive for ORC, PSOD will always result in an expected number 
of tests greater than or equal to the remaining tests that ORC performs. This is due to 
ORC looking at all possible configurations and PSOD using a search algorithm that 
does not necessarily find the optimal configuration.  
As we have discussed in this paper, hierarchical group testing has been applied in a 
number of areas. Our research shows that these applications could be improved upon if 
risk factor information can be incorporated into the testing process. To illustrate, 
consider again the Pilcher et al. (2005) example from Section 3.2. In their application, 
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the overall prevalence rate was p = 0.00021. Assuming no testing error, the expected 
number of tests for one group with their method is 1.3573. If subgroup sizes were 
selected based on this overall prevalence, we obtain E(T) = 1.3572 where 10 subgroups 
of size 9 would be used at stage 2, which is very similar to what was actually 
implemented. One would expect that individual probabilities of positivity would vary 
based on risk factors, but, unfortunately, this information is not available. However, if 
we suppose the individual probabilities had a beta distribution with a = 0.5 and same 
p, then the expected number of tests for one group is reduced to E(T) = 1.292, which is 
almost a 5% decrease. If a = 0.1 with the same p again, then E(T) = 1.199, which is a 
decrease of more than 11%. Given the number of individuals screened was 109,250, we 
can see a significant savings in tests could occur.    
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Disease Gender Specimen Count p  pˆ  Se Sp 
MLE 
of a 
 
MLE 
of p ˆ ˆ( )ikVar p  
Chlamydia 
Female 
Swab 14,503 0.069 0.066 92.8% 96.0% 2.5 0.067 0.001641 
Urine 4,970 0.080 0.083 80.5% 96.0% 1.1 0.087 0.005775 
Male 
Swab 1,909 0.157 0.145 92.5% 95.0% 1.0 0.149 0.016491 
Urine 6,139 0.081 0.089 93.0% 95.0% 1.8 0.090 0.003864 
Gonorrhea 
Female 
Swab 14,503 0.013 0.012 96.6% 98.0% 0.5 0.011 0.000236 
Urine 4,970 0.017 0.017 84.9% 98.0% 0.5 0.018 0.000613 
Male 
Swab 1,909 0.070 0.068 98.5% 96.0% 0.4 0.077 0.011453 
Urine 6,139 0.021 0.017 97.0% 96.0% 0.2 0.014 0.000952 
Table 3.1. Summary statistics for chlamydia and gonorrhea screening in 2009. The overall observed prevalence is denoted 
by p . The average estimated individual probability is denoted by pˆ . The maximum likelihood estimates (MLE) for a and 
p are found by fitting a beta distribution model to all estimated individual probabilities. The estimated variance of iˆkp  uses 
the beta distribution MLEs in its calculation. 
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Female/Urine Male/Urine 
Method I E(T)/N Change PSe PSp PPPV PNPV I E(T)/N Change PSe PSp PPPV PNPV 
H3 12 0.414 0.0% 52.19% 99.36% 88.11% 95.83% 
 
9 0.522 0.0% 80.44% 99.17% 90.54% 98.10% 
OH3 9 0.409 -1.2% 52.17% 99.35% 88.19% 95.83% 
 
7 0.517 -0.9% 80.44% 99.10% 89.91% 98.10% 
N-CRC3 16 0.394 -4.9% 52.19% 99.43% 89.49% 95.83% 
 
8 0.497 -4.8% 81.19% 99.06% 89.94% 98.27% 
N-ORC3 16 0.394 -4.9% 52.19% 99.43% 89.49% 95.83% 
 
8 0.497 -4.8% 81.19% 99.06% 89.94% 98.27% 
A-CRC3 16 0.391 -5.6% 52.56% 99.36% 88.78% 95.96% 
 
9 0.496 -5.0% 81.04% 99.06% 89.93% 98.27% 
A-ORC3 16 0.390 -5.8% 52.51% 99.37% 89.01% 95.95% 
 
9 0.496 -5.0% 81.04% 99.06% 89.93% 98.27% 
H4 20 0.370 -10.8% 42.05% 99.57% 89.90% 95.00% 
 
18 0.519 -0.6% 74.84% 99.26% 90.85% 97.57% 
OH4 19 0.354 -14.5% 42.05% 99.45% 87.93% 94.99% 
 
13 0.506 -3.1% 74.81% 99.24% 90.91% 97.56% 
N-CRC4 20 0.346 -16.4% 42.05% 99.62% 91.36% 95.00% 
 
16 0.488 -6.5% 75.88% 99.22% 91.09% 97.79% 
Female/Swab Male/Swab 
Method I E(T)/N Change PSe PSp PPPV PNPV I E(T)/N Change PSe PSp PPPV PNPV 
H3 9 0.431 0.0% 79.92% 99.51% 92.07% 98.59% 
 
9 0.685 0.0% 79.17% 98.74% 91.44% 96.55% 
OH3 7 0.434 0.6% 79.92% 99.46% 91.28% 98.59% 
 
7 0.665 -2.9% 79.16% 98.66% 91.30% 96.55% 
N-CRC3 8 0.420 -2.6% 80.70% 99.42% 91.01% 98.71% 
 
9 0.630 -8.0% 80.59% 98.52% 91.08% 97.05% 
N-ORC3 8 0.420 -2.6% 80.70% 99.42% 91.01% 98.71% 
 
9 0.630 -8.0% 80.59% 98.52% 91.08% 97.05% 
A-CRC3 9 0.418 -3.1% 80.28% 99.46% 91.61% 98.67% 
 
8 0.625 -8.7% 80.55% 98.60% 91.58% 97.06% 
A-ORC3 9 0.418 -3.1% 80.28% 99.46% 91.61% 98.67% 
 
8 0.624 -8.8% 80.57% 98.60% 91.60% 97.08% 
H4 18 0.422 -2.0% 74.17% 99.56% 92.35% 98.20% 
 
20 0.682 -0.4% 73.25% 98.90% 91.90% 95.62% 
OH4 13 0.417 -3.2% 74.17% 99.54% 92.11% 98.20% 
 
17 0.639 -6.7% 73.23% 98.55% 90.24% 95.60% 
N-CRC4 16 0.405 -5.9% 75.25% 99.53% 92.24% 98.35% 
 
20 0.611 -10.8% 75.03% 98.81% 92.31% 96.19% 
Table 3.2. Expected number of tests and accuracy measures for chlamydia screening, where N is the total number of 
individuals screened as given in Table 3.1. The “Change” column represents the percent improvement over homogeneous 
three-step (H3). 
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Female/Urine 
 
Male/Urine 
Method I E(T)/N Change PSe PSp PPPV PNPV I E(T)/N Change PSe PSp PPPV PNPV 
H3 20 0.168 0.0% 61.22% 99.89% 91.11% 99.32% 20 0.197 0.0% 91.28% 99.71% 84.73% 99.85% 
OH3 13 0.180 7.4% 61.20% 99.87% 89.68% 99.32% 15 0.206 4.4% 91.27% 99.63% 81.23% 99.85% 
N-CRC3 20 0.155 -7.5% 61.22% 99.92% 93.10% 99.32% 20 0.156 -20.6% 91.42% 99.81% 89.86% 99.87% 
N-ORC3 20 0.155 -7.5% 61.22% 99.92% 93.10% 99.32% 20 0.156 -20.6% 91.42% 99.81% 89.86% 99.87% 
A-CRC3 20 0.153 -8.8% 61.38% 99.91% 92.88% 99.34% 20 0.151 -23.1% 91.42% 99.80% 89.38% 99.88% 
A-ORC3 20 0.153 -8.8% 61.38% 99.91% 92.88% 99.34% 20 0.151 -23.1% 91.42% 99.80% 89.38% 99.88% 
H4 20 0.149 -11.0% 52.01% 99.95% 94.47% 99.16% 20 0.182 -7.7% 88.54% 99.84% 90.35% 99.80% 
OH4 19 0.148 -11.6% 52.01% 99.93% 92.81% 99.15% 19 0.174 -11.9% 88.53% 99.80% 89.17% 99.80% 
N-CRC4 20 0.142 -15.0% 52.01% 99.96% 96.13% 99.16% 20 0.137 -30.6% 88.96% 99.89% 93.81% 99.85% 
Female/Swab Male/Swab 
Method I E(T)/N Change PSe PSp PPPV PNPV I E(T)/N Change PSe PSp PPPV PNPV 
H3 20 0.151 0.0% 90.14% 99.91% 92.05% 99.88% 9 0.469 0.0% 95.57% 99.43% 92.55% 99.67% 
OH3 15 0.165 9.5% 90.15% 99.87% 89.20% 99.88% 7 0.443 -5.4% 95.57% 99.45% 93.30% 99.67% 
N-CRC3 20 0.133 -11.8% 90.30% 99.92% 93.24% 99.89% 13 0.371 -20.8% 95.80% 99.34% 92.46% 99.74% 
N-ORC3 20 0.133 -11.8% 90.30% 99.92% 93.24% 99.89% 13 0.371 -20.8% 95.80% 99.34% 92.46% 99.74% 
A-CRC3 20 0.132 -12.7% 90.26% 99.93% 93.81% 99.89% 13 0.362 -22.7% 95.77% 99.37% 92.82% 99.75% 
A-ORC3 20 0.132 -12.7% 90.26% 99.93% 93.83% 99.89% 13 0.362 -22.7% 95.76% 99.37% 92.84% 99.75% 
H4 20 0.141 -6.6% 87.08% 99.95% 95.13% 99.85% 9 0.475 1.3% 95.26% 99.49% 93.30% 99.65% 
OH4 19 0.140 -7.2% 87.08% 99.93% 93.80% 99.85% 15 0.420 -10.4% 94.14% 99.45% 93.68% 99.57% 
N-CRC4 20 0.123 -18.9% 88.00% 99.94% 94.57% 99.89% 20 0.332 -29.1% 94.57% 99.49% 94.50% 99.71% 
Table 3.3. Expected number of tests and accuracy measures for gonorrhea screening, where N is the total number of 
individuals screened as given in Table 3.1. The “Change” column represents the percent improvement over homogeneous 
three-step (H3).  
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Figure 3.1. Expected number of tests per individual with Se = 0.95 and Sp = 0.95. Each panel corresponds to a level of p. 
a  0, S = 3
a  0, S = 4
a = 0.1,  S = 3 a  ∞, S = 3
a = 0.1,  S = 4
a = 1,  S = 3
a = 1,  S = 4 a  ∞, S = 4
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Figure 3.2. Accuracy measures when p = 0.05 and Se = Sp = 0.95. 
a  0, S = 3
a  0, S = 4
a = 0.1,  S = 3 a  ∞, S = 3
a = 0.1,  S = 4
a = 1,  S = 3
a = 1,  S = 4 a  ∞, S = 4
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Chapter 4: Additional considerations 
4.1 Additional investigations into halving 
We present next a few interesting observations about halving. These observations 
show that an exact implementation of halving, while perhaps easy to implement, 
is not necessarily an optimal group testing procedure. 
4.1.1 I = 4 
Consider the case involving an initial group of size I = 4. If the initial group tests 
positive, the halving procedure splits the group into two subgroups of size 2. If 
either of these subgroups tests positive, individual testing is performed on those 
individuals within a positive subgroup. Interestingly, this procedure is always 
sub-optimal (in terms of the expected number of tests) to Dorfman’s procedure 
when Se = Sp = 1. To prove this result, let TDorf and Thalving denote random 
variables for the number of tests performed under the Dorfman and halving 
procedures, respectively. The expected number of tests is  
{ }4
1
( ) 1 4 1 (1 )Dorf i
i
E T p
=
= + - -  
and 
{ } { } { }4 2 4
1 1 3
4 2 4
1 1 3
4
1
( ) 1 2 1 (1 ) 2 1 (1 ) 2 1 (1 )
1 2 4 (1 ) 2 2 (1 ) 2 2 (1 )
2 (1 )
halving i i i
i i i
i i i
i i i
i
i
E T p p p
p p p
p
= = =
= = =
=
= + - - + - - + - -  
= + - - + - - + - -  
+ -
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{ }{ }
4 2 4
1 1 3
2 4
1 3
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( ) 2 1 (1 ) 1 (1 ) .
i i i
i i i
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Thus, E(Thalving) >E(TDorf) as long as p1 or p2> 0 and p3 or p4> 0, leading to 
Dorfman’s procedure being preferred in application. Perhaps the more important 
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consequence of this result is for I> 4. For these larger initial group sizes, halving 
should never be completely applied to a point of individual testing. Rather, once 
a sub-group size of 4 or less is reached, Dorfman’s procedure should be 
implemented to complete the decoding.   
Of course, testing error (Se and/or Sp¹ 1) typically occurs in most infectious 
disease applications. In Chapter 2, we saw that Dorfman’s procedure is usually 
not better than a three-step halving procedure. For example, when Se and Sp are 
different from 1 and I = 4, we have  
4
1
( ) 1 4 4(1 ) (1 ),Dorf e p e i
i
E T S S S p
=
= + + - - -  
and 
{ }
4
1
4
2
1
2 4
1 1
( ) 1 2 2(1 ) (1 )
4 4(1 )(1 ) (1 )
2 (1 ) (1 ) (1 ) .
halving e p e i
i
e p p e i
i
e p e i i
i i
E T S S S p
S S S S p
S S S p p
=
=
= =
= + + - - -
+ + - - - -
+ - - - + - 
 
If pi = 0.05 for all i = 1, …, 4 and Se = Sp = 0.95, then E(TDorf) = 1.87 and 
E(Thalving) = 1.81. 
4.1.2 I> 4 
Consider again the setting with no testing error, but now I> 4. Also, consider the 
situation where at least three steps are used for decoding. One can show that 
removing the second halving step can lead to a smaller expected number of steps. 
For example, suppose I = 16. A four-step halving implementation would use 
subgroups of size 8 (step 2), size 4 (step 3), and size 1 (step 4). Instead, if a 
three-step procedure was implemented where four subgroups of size 4 were 
constructed from the initial group (immediately going to step 3 of the four-step 
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halving procedure), this new three-step procedure would have a smaller expected 
number of tests.  
We can show that skipping a step leads to a smaller expected number of tests 
as follows. Consider a three-step procedure where step 2 has 4 groups the same 
size as the step 3 of a four-step halving procedure. Thus, we are essentially 
removing the second step from the four-step halving procedure to produce a new 
three-step procedure. Let T3-step and T4-step denote random variables for the 
number of tests performed under the three- and four-step procedures, 
respectively. The expected number of tests is 
2
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The last term in each equation is the same. Thus, by subtracting the two 
expressions, we obtain 
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Thus, four-step halving always results in a larger expected number of tests when 
pi>0 for at least one i = 1, …, / 2Ié ùê úê ú  and at least one i = / 2Ié ùê úê ú  + 1, …, I. This 
same result occurs whenever there are two subgroups at one step that would 
normally be split into two additional subgroups in a next step for halving.  
Similar to what we saw in Section 4.1.1, the above results do not hold true when 
testing error is present. 
4.2 PMF for generalized hierarchical retesting 
This section shows how to calculate recursively the PMF for the number of tests 
using a generalized hierarchical retesting procedure. We use the notation from 
Section 3.2.1 and modify the process and notation from Appendix A of Chapter 
2. As in Appendix A, we build from the second to last stage (s = S – 1), because 
this is the last time group sizes would be used. To begin, let a = Sp, b = 1 – Sp, c 
= 1 – Se, and d = Se. For every test, there are four possible combinations of test 
outcomes and true statuses, Gsj = 0 or 1 and sjG  = 0 or 1. In order to calculate 
the PMF for the number of tests, we begin by defining three sets of matrices for 
stage S – 1:  
2 j
a b
c d
é ùê ú= ê úê úë û
E  
a matrix of possible testing errors, 2 1, 1,( 0), ( 1)j S j S jP G P G- -
¢é ù= = =ë ûP    a vector of 
probabilities for the true statuses, and 2 1,0,j S jm -
¢é ù= ë ûT  a vector for the number of 
tests, where j = 1, …, cS-1. The first subscript of “2” denotes the second to last 
level, or base level, as done in Appendix A. For a two-stage procedure, these 
defined matrices are the final values. For example, in the simple case of 
Dorfman’s procedure, c1 = 1 and the PMF for number of tests 21 2= +T T j is 
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21 21( )¢¢P E , where j2is a 2´1 vector of 1’s added to account for the initial group 
test. 
For a three-stage procedure, we need to build E31, T31, and P31 by combining 
the matrices for the subgroups from the penultimate stage. If for example we 
have a group with I individuals m11 = 2, m21, and m22, we have 21 210, ,m
¢é ù= ë ûT
22 220, ,m
¢é ù= ë ûT 21 21 21( 0), ( 1) ,P G P G ¢é ù= = =ë ûP   22 22 22( 0), ( 1) ,P G P G ¢é ù= = =ë ûP    and 
21 22 2 .j= =E E E Our final matrices become 
31 21 2 2 22 11 4
21 21 22 22
22 21 22 22
[0, ]
[0,[0,0, , ] [0, ,0, ] [2,2,2,2]]
[0,2, 2, 2, 2] ,
m
m m m m
m m m m
¢ ¢ ¢ ¢ ¢ ¢= Ä + Ä + *
¢= + +
¢= + + + +
T T j j T j
 
31 21 22 21 21 22 22
21 22 21 22
21 22 21 22
11 11 21 22
11 21 22
[ ( 0), ( 1)] [ ( 0), ( 1)]
[ ( 0) ( 0), ( 0) ( 1),
( 1) ( 0), ( 1) ( 1)]
[ ( 0), ( 1 0 1),
( 1 1 0), (
P G P G P G P G
P G P G P G P G
P G P G P G P G
P G P G G G
P G G G P G
¢ ¢= Ä = = = Ä = =
= = = = =
¢= = = =
= = = Ç = Ç =
= Ç = Ç =
P P P    
   
   
   
   
11 21 221 1 1)] ,G G ¢= Ç = Ç = 
 
and 
( )31 3 3 21 22[ , ] || ([ , ]) .
a aab abb bab bbb
c acd add bcd bdd
a c Diag b d
c cad cbd dad dbd
c ccd cdd dcd ddd
é ùê úê úé ù ê ú¢ ¢ ¢= * * ´ Ä =ê ú ê úë û ê úê úê úë û
E j j E E  
where || denotes vertical concatenation, * denotes scalar multiplication, jm denotes 
a m´1 vector of 1’s, and Ä denotes a Kronecker product. The corresponding 
probabilities for 31 5= +T T j  can be found from 31 31( )¢¢P E , where we see that  
31 31 11 11 21 22
11 21 22 11 21 22
11 21 22
[ ( 0), ( 1 0 0),
( 1 0 1), ( 1 1 0),
( 1 1 1)].
P G P G G G
P G G G P G G G
P G G G
¢ = = = Ç = Ç =
= Ç = Ç = = Ç = Ç =
= Ç = Ç =
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For the above example, we do not differ much from the halving method in 
Appendix A, mostly in where we add in testing from earlier stages. However, in a 
generalized hierarchical retesting procedure, we could have more than 2 
subgroups at stage 2. For example, we could have m11 = 3, m21, m22, and m23. 
Then our matrices become 
31 21 2 2 22 2 4 22 11 8
22 22 21 21 22 21 22 21
23 23 23 23
23 22 23 22 21
23 21 22 21 23 22
[0 || [ ] ]
[0 || [0,0, , , , , , ]
[0, ,0, ,0, , 0, ] [3,3,3,3,3,3,3,3]]
[0,3, 3, 3, 3, 3,
3, 3,
m
m m m m m m m m
m m m m
m m m m m
m m m m m m
¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢ ¢= Ä + Ä Ä + + *
¢= + +
¢+ +
= + + + + +
+ + + + + +
T T j j T j j T j
21 3] ,m ¢+
 
31 21 22 23= Ä ÄP P P P  
and 
( )31 7 7 21 22 23[ , ] || ([ , ]) .a c Diag b dé ù¢ ¢ ¢= * * ´ Ä Äê úë ûE j j E E E  
Specifically, if I = 10, m11 = 3, m21 = 5, m22 = 4, and m23 = 0 our final  
[1,4,4,8,8,9,9,13,13] .¢=T  
We see repeats in the number of tests, because the 10th individual has finished 
testing at stage 2 and so the number of tests is not changed by its testing status, 
positive or negative. To get the PMF for the unique set of possible number of 
tests, we would sum the corresponding probabilities for the identical number of 
tests.  
For the general case, we build the PMF up from the penultimate step using 
the matrices  
*
1,
* 1, 1,1
0, 0, ,S s ji msj s i S s j ki i m
- ++
- - += +
¢ ¢é ù é ù¢ ¢= Å + *ê ú ê úë û ë ûT T j  
*
1,
* 1,1
,S s ji msj s ii i
- ++
-= += ÄP P  
and 
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( )* 1,* 1,1[ , ] || ([ , ]) ,S s ji msj k k s ii ia c Diag b d - ++ -= +é ù¢ ¢ ¢= * * ´ Äê úë ûE j j E  
for s = 3, …, S and j = 1, …, 1S sc - + , k is the value that makes parts conformable 
and can vary in value based on the number of subgroups at each stage and the 
number of individuals who finish testing early, i* is the last subscript for the 
subgroups split from the jth subgroup of the S – s + 1 stage, and we use Å  to 
denote the operation 
,B AÅ = Ä + ÄA B A 1 1 B  
where1B and 1A are matrices of 1’s with the dimensions of matrices B and A 
respectively. These differ from the halving functions, because for multiple 
subgroups at each stage we have to include all the splits. As we move up through 
the stages if there is individual testing that occurred at the earlier stage, we need 
to add additional  
sj
a b
c d
é ùê ú= ê úê úë û
E , 1, 1,( 0), ( 1)sj S s j S s jP G P G- + - +
¢é ù= = =ë ûP   , and 0, 0sj é ù= ë ûT  
for each j at the S – s + 1 stage such that 1, 0S s jm - + = .  
Our final resulting matrices will be 1ST , 1,SP and ES1. The corresponding 
probabilities for 1S k= +T T j  can be found from 1 1( )S S ¢¢P E . Because we may have 
repeats for the number of tests, we sum the probabilities over the corresponding 
unique number of tests in T to obtain the PMF.  
These operations can be continued for any number of steps, and our algorithm 
is designed to allow for any combination of final sub-group sizes. Large matrices 
result when S is not small (e.g., S≥ 6) and when cs the number of subgroups at 
each stage is large. This causes memory problems from using the matrix methods 
in R’s base package (R Development Core Team, 2013). However, this is not too 
limiting because S and number of subgroups are usually small in practice.  
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4.3 The CRC computational process 
To find the CRC by iterating through possible retesting configurations, we need 
to modify our notation from Chapter 3 in order to track all individuals until the 
final stage. In Chapter 3 if an individual had finished testing before the final 
stage S, a corresponding sub-group could no longer be split, which led to a msj = 
0 to signify individual testing had occurred (e.g., see Figures E.1 and E.2). For 
computational purposes, we now need to have all individual testing occur at the 
final stage. Therefore, we replace our msj notation with sjm
  as the number of 
subgroups a group would be split into. To illustrate, Figure 4.1 diagrams the five-
stage example given in Figure E.1. A yellow box indicates testing occurs while a 
pink box indicates no testing occurs. We can see that sjm
  = 1 for these pink 
boxes because the sub-group is not being split. The S = 5 final stage has the 
individual testing for all I = 10 individuals. Note that by removing the pink 
boxes and shifting the remaining subgroups up in the diagram, we obtain Figure 
E.1. To distinguish the differences between Chapter 3 and here, we call a 
diagram like in Figure 4.1 a “computational configuration” as opposed to a 
retesting configuration in Chapter 3. 
With these computational configurations, the expected number of tests given 
in Equation 3.1 becomes  
1
{( ): 1}1 1
( ) 1 { 1} ,
s
sj
cS
sj sj s j
s j Gs j
E T t m P G
-
¢ ¢
¢ ¢ == =
æ ö÷ç= + = ÷å å ç ÷÷çè ø
 
 
where we include the indicator function tsj to account for subgroups that are not 
actually tested. The value of tsj is 1 if sjm
 > 1, which allows us to include the 
{( ): 1}
{ 1}
sj
sj s j
s j G
m P G ¢ ¢
¢ ¢ =
æ ö÷ç = ÷ç ÷÷çè ø
   contribution to E(T). The value of tsj is 0 when sjm
  = 1, 
because either no test is performed or individual testing is performed at stage S. 
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Figure 4.1 shows tsj in the context of the five-stage example. With this 
formulation, note that 1s
c
sjj I I= =å  for all s = 1, …,S.  
All possible computational configurations can be defined by finding 
sj
m  for s 
= 2, …,S – 1, and j = 1, …, cs so that the following conditions are met 
Condition 1. 
1
1 1
sj s s
m c c+£ £ - +  
Condition 2. 
11
,s
c
sj sj
m c += =å   
where cS = I. Condition 1 is simply saying that each subgroup must contain at 
least one subgroup for the next stage. The upper limit follows because if each 
must contain at least one, then no single subgroup could contain more than the 
total subgroups for the next stage minus the number of other subgroups at the 
given stage. For 
sj
m  at either extreme of Condition 1, we say that we are at an 
edge. Additionally, each set of 
sj
m  defines the number of individuals in each 
subgroup at each stage for the computational configuration, as can be seen in 
Figure 4.1. 
To facilitate iterating through the computational configurations when finding 
the CRC, define 1( ,..., )ss s scm m ¢=m    as a vector indicating the number of 
subgroups that a positive group at stage s will be split into for all cs subgroups. 
For example, Figure 4.2 illustrates a computational configuration corresponding 
to a retesting configuration first discussed in Chapter 3 (Figure E.2) where 
1 3=m , 2 (3,3,1)¢=m  and 2 (5,3,3,2,1,1,3)¢=m . For a given number of 
subgroups cs, with s = 2, …,S – 1, we perform the following:  
1. Start with the minimum number of subgroups at each stage. For a three-
stage procedure, this means we start with c2 = 2. For a four-stage 
procedure, this means we start with c2 = 2 and c3 = 3, because the third 
stage must have at least one more subgroup than the second.  
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2. Choose an initial configuration of sm

 with s = 2, …,S – 1 for the given 
number of subgroups and calculate E(T).  
3. Move one vertex in each plausible direction from the initial configuration 
and calculate the change in E(T) at these points (i.e. each possible 
configuration is represented by a vertex in n  space, connected to every 
other possible configuration by simple transformations, where 
1
2
S
ssn c
-
== å ). 
4. If there is no decrease in E(T), then our initial configuration is the best for 
this number of subgroups. Otherwise, find the direction of largest decrease 
in E(T) and continue moving to vertices in the direction of largest 
decrease until reaching an edge or until E(T) stops decreasing in that 
direction. The configuration with this new smallest E(T) has applied the 
same process outlined in 3.  
This process is repeated for other number of subgroups cs, where the cs values 
are increased each time in an iterative manner. The configuration with the 
smallest E(T) for all possible number of subgroups is the CRC. Alternatively, 
after two increases in cS – 1 with no decrease in the minimum E(T) during the 
iterative procedure, the process is stopped and the smallest E(T) found is treated 
as its smallest possible value. The corresponding configuration would then be 
taken as the CRC. Through observing a number of examples, this alternative 
method appears to work just as well as finding E(T) for all possible numbers of 
subgroups and it substantially reduces run times. The computational 
configuration corresponding to the smallest E(T) is used as the CRC.  
As an example of how we move between vertices, suppose for a four-stage 
procedure we had c2 = 3 and c3 = 6 as the number of subgroups, an initial 
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configuration of 1m

 = 3, 2m

 = (3, 2, 1)¢ and 3m  = (3, 2, 1, 2, 1, 1)¢, and an 
initial group size of I = 10. To move one vertex, we change individual elements 
in 2m

and/or 3m

 by +1 for one subgroup and -1 for another subgroup. For 
example, 2m

 might change to (2, 2, 2)¢ resulting in, say, 2m  = (-1, 0, 1)¢. Also, 
3m

 might change to (4, 2, 1, 1, 1, 1)¢ resulting in 3m  = (1, 0, 0, -1, 0, 0)¢. 
Note that both 2m

 and 3m

 can change simultaneously. 
Finding the CRC requires an initial starting configuration. For a three-stage 
procedure with a given number of subgroups at stage 2, this is simply done by 
setting 
2
1
j
m =  for j = 2, …,c2 and 21 2 1m I c= - + ; that is 2m

 = (I – c2 + 1, 1, 
…, 1)¢. Starting with this configuration is intuitive because individuals are 
ordered by their probabilities of positivity. Thus, individuals with the largest 
probabilities are tested individually, and individuals with the lowest probabilities 
are tested as a group. When we have a high level of heterogeneity among the 
individual probabilities, we have found that this method is very effective and 
quick at finding the optimal configuration. However, when there are groups with 
low heterogeneity among individual probabilities, the CRC takes much longer to 
find its configuration. This is because the ORC would have subgroups with 
individuals more evenly divided between them than when a high level of 
heterogeneity exists. Despite the CRC taking a longer time, we would like to 
point out that the CRC always matches ORC for our beta distribution examples 
in Chapter 3.  
If we pick the initial computational configuration for the four-stage 
procedures similarly to how we did for the three-stage procedures with 2m

 = (c3 
– c2 + 1, 1, …, 1)¢, and 3m  = (I – c3 + 1, 1, …, 1)¢, the CRC generally finds the 
ORC for highly heterogeneous groupings, but does poorly as heterogeneity 
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decreases. If however, we choose 2m
 ≈ (c3/c2, …, c3/c2)¢, and 3m ≈ (I/c3, …, 
I/c3)¢, where we use “≈” to mean approximately because the fractions may not be 
integers, the CRC finds the ORC for low heterogeneity relatively well, but does 
poorly when there is a high level of heterogeneity. Because of this, we start at 
both configurations for a four-stage procedure to better our chances of finding (or 
coming close to) the ORC. While these are not the only possible starting 
configurations, our results in Chapter 3 indicate that our choices end up working 
very well. 
4.4 R functions 
In this section, we show how to use four functions that can be used to implement 
the methods described in Chapters 2 and 3. First, beta.dist() computes the 
expected ordered probabilities from a beta distribution. Second, halving() 
computes the PMF for the halving procedure. Third, hierarchical.desc() 
returns a variety of information for hierarchical group testing, including the 
expected number of tests and accuracy measures. Finally, get.CRC() is the 
general hierarchical optimization function that finds the CRC or ORC for a given 
set of individual probabilities. Appendix I contains the R documentation for these 
functions.  
4.4.1 Expected value of order statistics from a beta distribution 
In Chapters 2 and 3, we use the order statistics from beta distributions to 
examine how well our proposed group testing procedures work. Our function 
beta.dist() computes these order statistics. The argument grp.sz is used to 
specify the initial group size and the arguments p and alpha are used to specify 
the distribution using the parameterization given in Section 3.3. Alternatively, 
the arguments alpha and beta can be used to parameterize the distribution in 
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the more conventional form as given by Casella and Berger (2002, p. 623). For 
example, suppose E(pi) = 0.05 for i = 1, …,  16 and a = 1. Below are the 
corresponding expected values of the order statistics.  
 
> p1 <- beta.dist(p = 0.05, alpha = 1, grp.sz = 16, plot = TRUE)  
>round(p1, 4) 
 [1] 0.0033 0.0068 0.0105 0.0145 0.0188 0.0234 0.0286 0.0342 
 [9] 0.0405 0.0477 0.0560 0.0658 0.0779 0.0938 0.1171 0.1612 
A plot of the distribution with the expected values of the order statistics is 
created by using the plot = TRUE argument. The plot for p1 is given in Figure 
4.3. 
4.4.2 PMF for the halving procedure 
The halving() function returns the PMF, E(T), and Var(T) for the halving 
procedure up to five steps. This function has the required argument p 
representing a vector of individual probabilities. The optional arguments include 
se for the sensitivity (default is se = 1), sp for the specificity (default is sp = 
1), stages for the number of steps (default is stages = 2), and order.p for 
whether or not to order the individual probabilities within p (default is order.p 
= TRUE)  
As a first example of using the function, consider a homogeneous set of 
individual probabilities where pi = 0.05 for i = 1 … 16, Se = Sp = 1, and 3 steps: 
 
> ex1 <- halving(p = rep(x = 0.05, times = 16), stages = 3) 
> ex1 
$pmf 
num.testsprob.tests 
1          1     0.4401 
2          3     0.0000 
3         11     0.4466 
4         19     0.1133 
$et 
[1] 7.50502 
$vt 
[1] 39.04807 
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Notice that the number of tests t can only be t = 1, 11, and 19 in this setting, 
where t = 3 is not possible because there is no testing error. Two additional 
examples where E(pi) = 0.05 are given below: 
 
> ex2 <- halving(p = rep(x = 0.05, times = 16), stages = 3, se =  
0.95, sp = 1) 
> p1 <- beta.dist(p = 0.05, alpha = 1, grp.sz = 16) 
> ex3 <- halving(p = p1, stages = 3, se = 0.95, sp = 1) 
 
>data.frame(t = ex1$pmf[,1], ex1 = ex1$pmf[,2], ex2 = ex2$pmf[,2],  
ex3 = ex3$pmf[,2], row.names = NULL)  #PMF 
t    ex1    ex2    ex3 
1  1 0.4401 0.4681 0.4612 
2  3 0.0000 0.0215 0.0240 
3 11 0.4466 0.4133 0.4581 
4 19 0.1133 0.0971 0.0568 
>data.frame(ex1 = ex1$et, ex2 = ex2$et, ex3 = ex3$et) #E(T) 
      ex1      ex2      ex3 
1 7.50502 6.923968 6.651044 
>data.frame(ex1 = ex1$vt, ex2 = ex2$vt, ex3 = ex3$vt) #Var(T) 
       ex1      ex2      ex3 
1 39.04807 37.78906 32.36854 
The second example is for a homogenous case with Se = 0.95 and Sp = 1, and the 
third example uses ordered halving where the expected order statistics from a 
beta distribution with p = 0.05 and a = 1 are used. Comparing the two 
homogeneous cases, we see that the expected number of tests decreases for the 
case with testing error due to now the possibility of false negative groups or 
subgroups. A further reduction in the expected number of tests occurs for ordered 
halving illustrating the benefits extolled in Chapter 2.  
4.4.3 Descriptive information for generalized hierarchical group testing 
procedure 
The hierarchical.desc() function computes the expected number of tests 
and measurements of accuracy for two-, three-, or four-stage hierarchical group 
testing. This function has the required argument p representing a vector of 
individual probabilities. The optional arguments include se for the sensitivity 
(default is se = 1), sp for the specificity (default is sp = 1), stages for the 
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number of steps (default is stages = 2), and order.p for whether or not to 
order the individual probabilities within p (default is order.p = TRUE). The 
arguments I2 and I3 define the number of individuals at each subgroup in 
stages 2 and 3 and are used to define the retesting procedure considered. The 
default retesting procedure is two-stage (Dorfman), which is equivalent to when 
I2 = NULL and I3 = NULL. To get three-stage results, I2 needs a vector with 
the number of individuals in each subgroup at stage 2 and I3 = NULL. To get 
four-stage results, I2 and I3 need vectors with the number of individuals in each 
subgroup at stage 2 and stage 3, respectively. For example, with Se = 0.95 and Sp 
= 1, and the expected order statistics from a beta distribution with p = 0.05 and  
a = 1, we get the same E(T) found for three-stage halving by using I2 = c(8, 
8) and I3 = NULL. 
 
> p1 <- beta.dist(p = 0.05, alpha = 1, beta = NULL, grp.sz = 16) 
> ex4 <- hierarchical.desc(p = p1, se = 0.95, sp = 1, I2 = c(8, 8),  
I3 = NULL) 
> ex4 
[1] "Three-stage procedure considered" 
$ET 
[1] 6.651044 
$stages 
[1] 3 
$group.size 
[1] 16 
$I2 
[1] 8 8 
$I3 
[1] "individual testing" 
$m1 
[1] 2 
$m2 
[1] 8 8 
$m3 
[1] "individual testing" 
$individual.testerror 
p    pse.vec   psp.vec pppv.vec pnpv.vec 
1  0.003278689 0.857375       1        1  0.9995311 
<Output edited> 
16 0.161210126 0.857375       1        1  0.9733197 
$group.testerror 
PSe    PSp       PPPV      PNPV  
0.8573750 1.0000000 1.0000000 0.9925493  
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$individual.probabilities 
 [1] 0.003278689 <Output edited> 0.161210126 
The output produced provides descriptive information about the retesting 
procedure. The testing errors are given for the individuals in the group and for 
the group as a whole; these measures are calculated using the formulas defined in 
Section 3.2.3. The function also provides m1, m2, and m3 as the numbers of 
subgroups that each positive testing group will split into at the next stage. 
4.4.4 Optimal or candidate retesting configuration 
The find.CRC() function finds the ORC or CRC to use with hierarchical group 
testing.  Its arguments include p as a vector of individual probabilities, se for the 
sensitivity (default is se = 1), sp for the specificity (default is sp = 1), 
stages for the number of stages (default is stages = 2), and every case 
for the ORC (= TRUE) or the CRC (= FALSE). The function finds the CRC by 
default. If the ORC is chosen instead, a warning is provided that it may take a 
long period of time to complete the calculations. The function uses 
hierarchical.desc() to produce the expected number of tests and accuracy 
measures for the configuration chosen. For example, we show below how to find 
the CRC for a three-stage procedure, with Se = 0.95, Sp = 1 and probabilities 
that are the expected order statistics from a beta distribution with p = 0.05 and 
a = 1. 
 
> p1 <- beta.dist(p = 0.05, a = 1, b = NULL, grp.sz = 16) 
> ex5 <- get.CRC(p = p1, se = .95, sp = 1, stages = 3) 
[1] "Three-stage procedure considered" 
> ex5 
$ET 
[1] 5.460507 
$stages 
[1] 3 
$group.size 
[1] 16 
$I2 
[1] 7 4 3 2 
$I3 
[1] "individual testing" 
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$m1 
[1] 4 
$m2 
[1] 7 4 3 2 
$m3 
[1] "individual testing" 
$individual.testerror 
 p    pse.vec psp.vec pppv.vec pnpv.vec  
1  0.003278689 0.857375       1           1   0.9995311 
<Output edited> 
16 0.161210126 0.857375       1           1   0.9733197 
$group.testerror 
PSe   PSp       PPPV      PNPV  
0.8573750 1.0000000 1.0000000 0.9925493  
$individual.probabilities 
[1] 0.003278689 <Output edited> 0.161210126 
Notice that the expected number of tests for this configuration is smaller than as 
shown for halving earlier with the same number of stages and testing error. 
4.5 Future research 
We have repeatedly shown in this dissertation that taking advantage of covariate 
information can decrease the number of tests needed for specific group testing 
procedures. We describe next extensions to our proposed methods and other ideas 
for future exploration. First, we discuss how group testing procedures can be used 
under specific laboratory conditions. Second, many screening procedures have 
some type of confirmation testing; i.e., after an initial screening, a more accurate 
test is used to double check if any positive individuals have been missed. It may 
be useful to apply the extra covariate information to these confirmation 
situations as well. Finally, the computational process for finding the CRC and 
ORC could be improved by using parallel processing. 
4.5.1 High throughput testing situations 
Many high throughput testing systems are available for diagnostic and chemical 
screening situations. High throughput systems allow for multiple simultaneous 
and automated testing to increase how quickly tests can be performed. One type 
of test used in these settings is an enzyme-linked immunosorbent assay (ELISA). 
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Equipment for ELISA testing is available in many forms. For example, ELISA 
tests can be done on 96 well plates (8 by 12), which can be processed and tested 
in single-channel (one well at a time), multichannel (rows of 8 or 12 at a time), 
semi-automated (one strip or plate at a time), or fully automated (multiple plates 
at a time) systems (IDEXX 2010). Which system is used depends on the type of 
screening being performed, training of personnel, and financial considerations. 
Ultrahigh throughput chemical compound screening systems can even screen up 
to 100,000 compounds per day (Remlinger, 2006). Understanding how retesting 
procedures can by utilized in these processes is very important to decide if a 
retesting procedure should be used and which one.  
For example, one 96 well ELISA plate performs 96 evaluations. This could be 
used to immediately screen 96 individuals or alternatively 96 pooled specimens. 
With an initial size for groups of I = 10 and an overall prevalence of p = 0.01, 
one plate could provide the initial screening of 960 individuals, where 
approximately 810 to 920 individuals would be classified as negative. This 
approximation comes from using a normal approximation to a binomial  
(
0.975
96 (1 ) / 96Zq q qé ù -ê úë û where 
101 (1 0.01)q = - - ). The remaining individuals 
would need to be retested to diagnose the positive individuals. A Dorfman 
procedure would likely need only 1 or 2 more plates to complete identification of 
all positive individuals. This would save approximately 714 to 824 tests or 7 to 8 
plates for classifying the 960 individuals. While this is a good improvement, the 
number of tests saved could be further reduced with more sophisticated retesting 
procedures. However, depending on how we order the tests, retesting procedures 
may not improve the number of plates used.  
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To evaluate how an overall process is improved by some retesting method, we 
will need to determine how well it can save time and reduce costs while 
improving or maintaining accuracy of results. Some factors that may affect how 
an overall process performs in comparison to others are the total number of tests 
used, the total number of plates used, the ease of implementation/automation, 
the efficient use of testing material, etc. Two-stage procedures such as Dorfman 
or multi-array testing would be easiest to implement and measure possible 
improvements. Multiple stage procedures such as Sterrett would be more difficult 
to implement and evaluate.  
The retesting methods we have looked at treat an initial group as a contained 
testing unit. In a high throughput testing environment with multiple 
simultaneous tests being performed, it may be useful to look at retesting 
procedures that combine individuals across positive groups in the retesting phase 
(Sobel and Groll, 1958). For example, if we have two positive groups of size ten, 
it may be useful to retest the five lowest probability individuals from each group 
in one new group, while retesting the five highest probabilities from each group 
individually. 
4.5.2 Changing assays 
In many situations, there are two types of assays used. First, a less expensive 
assay with greater testing error is used, and second, a confirmatory assay that is 
more expensive but with higher accuracy is used. Additionally, a commonly used 
assumption in group testing is that sensitivity and specificity are the same for 
different sized groups that use the same assay; however, some research has shown 
they can vary for different group sizes and taking possible variations into account 
can improve estimation (McMahan, 2013). The research in this dissertation 
81 
 
 
assumes the same assay or, at least, the same sensitivity and specificity is used at 
each stage of testing. Future research could incorporate initial (lower accuracy) 
and confirmatory (higher accuracy) assays into the testing protocol.  
One possible method to investigate involves immediately placing in the higher 
accuracy testing path any individuals whose probability of a false positive from 
the lower accuracy assay is large. How large and at what stage of retesting would 
be of future research interest.  
A second method might be to stop testing individuals with the lower accuracy 
tests if a maximum expected number of positive individuals is reached, either for 
the entire population being screened or group by group. Since individuals being 
positive or negative are a series of Bernoulli trials, finding a PMF for the number 
of positive individuals can be found and used to find an upper bound for the 
likely total number of positive individuals expected in either an entire population 
or group by group. Instead of looking at the maximum number of individuals 
who are positive, we could alternatively look at the maximum number testing 
positive. Equation 3.2 can be used to find the probability each individual tests 
positive within the framework of a specific retesting procedure. These 
probabilities could be used in place of the individual probabilities of being 
positive to find a likely upper bound for the number of individuals testing 
positive.  
4.5.3 Parallel processing 
With the release of R 2.14.0, the parallel package for parallel processing was 
made part of the default installation for R (R Development Core Team, 2013). 
Parallel processing allows one to split-up computations to multiple cores of a 
single processor or across several processors. The end result is potentially large 
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reductions in computation time to complete a task. The nature of a search for an 
ORC would be well suited for improvement through using parallel processing 
techniques, because it could repetitiously iterate through possible configurations. 
Running simultaneous iterations of separate collections of possible configurations 
could greatly reduce the computation time making larger group sizes 
computationally possible. 
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Figure 4.1. Possible, not necessarily optimal, computational configuration for a group size of 10, using notation for 
iterating through possible configurations. Figure E.1 shows the retesting configuration associated with this computational 
configuration. 
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Figure 4.2. CRC computational configuration using notation for iterating through possible configurations for an expected 
ordered beta distribution with I = 18, p = 0.05, and a = 1, also Se = 0.95 and Sp = 0.95. Figure E.2 shows the retesting 
configuration used by this computational configuration. 
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Figure 4.3. Output plot from p1 <- beta.dist(p = 0.05, a = 1, b = NULL, grp.sz = 16, plot = 
TRUE). The numerical values for the expectations are denoted by the short vertical lines. 
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Appendix A: PMF for halving 
This appendix shows how to calculate recursively the PMF for the number of 
tests using the halving procedure. To begin, consider the case of S = 2 
(Dorfman’s procedure), and let a = Sp, b = 1 – Sp, c = 1 – Se, and d = Se. There 
are four possible combinations of test outcomes and true statuses for this 
situation because G1,1 = 0 or 1 and 1,1G  = 0 or 1. In order to find the PMF for 
the number of tests with S = 2, let  
2
a b
c d
é ùê ú= ê úê úë û
E  
be a matrix of possible testing errors, 
1,12, 1,1 1,1( 0), ( 1)I P G P G
¢é ù= = =ë ûP    be a vector 
of probabilities for the true statuses, and 
1,12, 1,11,1I I
¢é ù= +ë ûT  be a vector for the 
number of tests. Note that the subscript II1,1 is used to denote the number of 
individuals in the top node of the group testing procedure. The PMF for 
1,12,IT is 
1,12, 2I
¢P E .  
For the case of S = 3, we use the fact that the two sub-groups containing I2,1 
and I2,2 individuals can be tested as separate 2-step procedures. This leads to the 
matrices  
( )3 2 2[ , , , ] || ([ , , , ]) ,
a aab abb bab bbb
c acd add bcd bdd
a c c c Diag b d d d
c cad cbd dad dbd
c ccd cdd dcd ddd
é ùê úê úé ù ê ú¢= ´ Ä =ê ú ê úë û ê úê úê úë û
E E E
 
1,1 2,1 2,23, 2, 2,
1,1 1,1 2,1 2,2
1,1 2,1 2,2 1,1 2,1 2,2
[ ( 0), ( 1 0 1),
( 1 1 0), ( 1 1 1)] ,
I I I
P G P G G G
P G G G P G G G
= Ä
= = = Ç = Ç =
¢= Ç = Ç = = Ç = Ç =
   
     
P P P
 
and 
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1,1 2,1 2,23, 2 2, 2, 2 4 2,1 2,2 1,11, 1,3,3 ,3 ,3 ,I I I I I I
¢ ¢é ù é ù¢ ¢ ¢= Ä + Ä + = + + +ê ú ë ûë ûT j T T j j  
where || denotes vertical concatenation, jm denotes a m´1 vector of 1’s, and Ä 
denotes a Kronecker product. The corresponding probabilities for 
1,13,IT  can be 
found from 
1,13, 3I
¢P E . After summing these probabilities over the same number of 
tests in 
1,13,IT , we obtain the PMF for the unique number of tests.  
To generalize for any number of steps S, we start with the last step before 
individual testing and build up. Let 
1,2, 1,1,1S jI S jI- -
¢é ù= +ë ûT , 
1,2, 1, 1,( 0), ( 1)S jI S j S jP G P G- - -
¢é ù= = =ë ûP   for j = 1, …, 2S-2, and 2E be the same as 
before. In reverse order from how the testing is actually done, we successively 
build new matrices 
2
1, 2,2 1 2,2, 1, 1,1, ,S s j S s j S s js I k s I s I k k- + - + - - +- -
¢é ù¢ ¢ ¢= Ä + Ä +ê úë ûT j T T j j  
1, 2,2 1 2,2, 1, 1, ,S s j S s j S s js I s I s I- + - + - - +- -= ÄP P P  
and 
( )1 1[ , ] || ([ , ])s m m s sa c Diag b d - -é ù¢ ¢ ¢= ´ Äê úë ûE j j E E  
furs = 3, …, S and j = 1, …, 2S-s, where m is 1 less than the number of rows in 
1 1s s- -ÄE E  and k is the number of rows in 2,21, S s js I - +-T . Our final resulting matrices 
will be 
1,1,S IT , 1,1, ,S IP and ES. The corresponding probabilities for 1,1,S IT  can be 
found from 
1,1,S I S
¢P E . We sum these probabilities over the same number of tests in 
1,1,S IT  to obtain the PMF for the unique number of tests.  
These operations can be continued for any number of steps, and our algorithm 
is designed to allow for any combination of final sub-group sizes. Large matrices 
result when S is not small (e.g., S = 6, E6 requires a 65,536 x 458,329 matrix) 
causing memory problems from using the matrix methods in R’s base package (R 
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Development Core Team, 2013). However, this is not too limiting because S is 
usually small in practice.  
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Appendix B: Mean and variance for number 
of tests 
This appendix shows how to derive the mean and variance for the number of 
tests used in a halving procedure. We initially assume there are no testing errors 
and three steps only. First, we rewrite ( | )vecE T p  and 2( | )vecE T p  for a group of 
size II1,1 as 
1,1 2,1 1,1
2,1
2,1 2,2
1 1 1
( | ) 1 2 1 1 1(1 ) (1 ) (1 )
I I I
i i i
i i i I
vecE T I Ip p p
= = = +
ì üï ïï ï- - -  í ý ì ü ì üï ï ï ïï ï ï ï= + - + - + -í ý í ýï ï ï ïï ï ï ïîï ïï ïî þ þ î þ
p
 
and 
2,1 1,1
2,1
2 2
2,1 2,1 2,2 2,
2
1 1
2( | ) 1 (6 1 (1) )) (6 1 (1 )
I I
vec
i i
i i I
E T p pI I I I
= = +
ì ü ì üï ï ï ïï ï ï ï= + + - - + + - - + í ý í ýï ï ï ïï ï ï ïî þ î þ
p
2,1 1,1 1,1
2,1
2,1 2
1 1
,
1
22 1 (1 ) (1 ) (1 )
I I I
i i i
i i I i
p p pI I
= = + =
ì üï ïï ï- - - - + - +  í ýï ïï ïî þ
1,1
1
8 1 (1 ) .
I
i
i
p
=
ì üï ïï ï- -í ýï ïï ïî þ
 
These expressions are used to find 
1,1 1,1 1,1 2,1
1 1 1 1
2,1( | ) 4 (1 ) 1 (1 ) 4 (1 ) 1 (1 )
I I I I
vec
i i i i
i i i i
Var p p pIT p
= = = =
ì ü ì üï ï ï ïï ï ï ï= - - - + - - - +   í ý í ýï ï ï ïï ï ï ïî þ î þ
p
1,1 1,1 2,1 2,1
2,1
2
2,2 2,
1 1 1 1
14 (1 ) 1 (1 ) (1 ) 1 (1 )
I I I I
i i i i
i i I i i
I Ip p p p
= = + = =
ì ü ì üï ï ï ïï ï ï ï- - - + - - - +   í ý í ýï ï ï ïï ï ï ïî þ î þ
1,1 1,1
2,1 2,11
2
2,2
1
(1 ) 1 (1 ) .
I I
i i
i I i I
I p p
= + = +
ì üï ïï ï- - - í ýï ïï ïî þ
 
When all of the individual probabilities are equal, we obtain 
2,1 2,2
2,1 2,2(1 ) } (( | ) 1 1 ) } (1 ) }2{1 {1 {1
I IIE T Ip I p p= + - + - +- ---p  
and 
2,2 2,1 2,1
2,1( | ) (1 ) {1 (1 ) } 4 (1 ) (1 )4 {1 (1 ) }
I I II IVar T p p I p p p= - - - + - - - - +p
2,1 2,2 2,2
2,24 (1 ) (1 ) {1 (1 ) }
I I II p p p- - - - + 
2,1 2,1 2,2 2,22 2
2,1 2,2(1 ) {1 (1 ) } (1 ) {1 (1 ) },
I I I II p p I p p- - - + - - -  
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where p is a I1 vector of equal individual probabilities (i.e., pi = p for i =1, …, 
I).  
When pi are independent random variables with E(pi) = p for i = 1, …, I, we 
obtain  
2,1 2,2
2,22,1
( ) { ( | )} 1 2{1 (1 ) }
1 (1 ) } {1 (1 ){
( | ).
}
vec I
I I
E T E E T p
p II
E T
p
= = + - - +
- - + - -
=
p
p
 
Therefore, the expected number of tests is the same as when the individual 
probabilities are all equal (i.e., a homogeneous population).  
To find the variance of the number of tests (still with pi as independent 
random variables and E(pi) = p for i = 1, …, I), we use the expression ( )Var T =
{ ( | )} { ( | )}vec vecE Var T Var E T+p p . The first term is 
1,1
2
1
{ ( | )} 4 (1 ) (1 ) (1 )
I
vec I I
i
i
VE Var T p a pr p
=
é ùì üï ïï ïê ú= - - - - - +í ýê úï ïï ïî þë û
p
2,1
2,2 2,1 2,12
2,1
1
4 (1 ) (1 ) (1 ) (1 )
I
I I I
i
i
I Varp p p p
=
é ùì üï ïï ïê ú- - - - - - +í ýê úï ïï ïî þë û
1,1
2,1 2,2 2,2
2,1
2
2,2
1
4 (1 ) (1 ) (1 ) (1 )
I
I I I
i
i I
VaI p p p pr
= +
é ùì üï ïï ïê ú- - - - - - +í ýê úï ïï ïî þë û
2,1
2,1 2,122
2,1
1
(1 ) (1 ) (1 )
I
I I
i
i
I p p pVar
=
ì üï ïï ï- - - - -í
é ùê ú +ê úë ïï ïî û
ýïþ
1,1
2,2 2,2
2,1
22
2,2
1
(1 ) (1 ) (1 ) ,
I
I I
i
i I
VarI p p p
= +
é ùì üï ïï ïê ú- - - - -í ýê úï ïï ïî þë û
 
and the second term is 
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1,1 2,1 1,1
2,1
2 2
2
1 1 1
,1 2,2{ ( | )} 4 (1 ) (1 ) (1 )
I I I
vec
i i i
i i i I
Var E T Var p p pI Var I Var
= = = +
ì ü ì ü ì üï ï ï ï ï ïï ï ï ï ï ï= - - - +  í ý í ý í ýï ï ï ï ï ïï ï ï ï ï ïî þ î þ î þ
+ +p
1,1 2,1 1,1 1,1
2,1
2,1 2
1 1 1 1
,2(1 ) (1 ) (1 ) (14 , 4 , )
I I I I
i i i i
i i i i I
p p p pI Cov I Cov
= = = = +
+ì ü ì üï ï ï ïï ï ï ï- - - - +   í ý í ýï ï ï ïï ï ï ïî þ î þ
2,1 1,1
2,1
2,1 2
1 1
,2 (1 ), (12 ) .
I I
i i
i i I
p pI I Cov
= = +
ì üï ïï ï- - í ýï ïï ïî þ  
In order to simplify the above expressions, one can show  
1,1
2 2
1
(1 ) { ( ) (1 ) } (1 ) ,
I
I I
i i
i
Var p Var p p p
=
ì üï ïï ï- = + - - -í ýï ïï ïî þ  
2,1 1,1
2,11 1
(1 ), (1 ) 0,
I I
i i
i i I
Cov p p
= = +
ì üï ïï ï- - = í ýï ïï ïî þ  
1,1 2,1 2,1
2,2
2,2 2,1 2,1
1 1 1
22
(1 ), (1 ) (1 ) (1 )
(1 ) [{ ( ) (1 ) } (1 ) ]  
I I I
I
i i i
i i i
I I I
i
Cov p p p Var p
p Var p p p
= = =
ì ü ì üï ï ï ïï ï ï ï- - = - -  í ý í ýï ï ï ïï ï ï ïî þ î þ
= - + - - -
 
1,1 1,1 1,1
2,1
2,1 2,1
2,1 2,2 2,2
1 1 1
22
(1 ), (1 ) (1 ) (1 )
(1 ) [{ ( ) (1 ) } (1 ) ],
I I I
I
i i i
i i I i I
I I I
i
Cov p p p Var p
p Var p p p
= = + = +
ì ü ì üï ï ï ïï ï ï ï- - = - -  í ý í ýï ï ï ïï ï ï ïî þ î þ
= - + - - -
 
and the variances for 2,11(1 )
I
ii p= - and 1,1 2,1 1(1 )I ii I p= + -  are similar. Substituting 
into { ( | )}vecE Var T p  and { ( | )}vecVar E T p  gives us 
2{ ( | )} 4[(1 ) { ( ) (1 ) } ]vec I IiE Var T p Var p p= - - + - +p
2,2 2,1 2,12
2,14 (1 ) [(1 ) { ( ) (1 ) } ]
I I I
iI p p Var p p- - - + - +
2,1 2,2 2,22
2,24 (1 ) [(1 ) { ( ) (1 ) } ]
I I I
iI p p Var p p- - - + - +
2,1 2,12 2
2,1[(1 ) { ( ) (1 ) } ]
I I
iI p Var p p- - + - +
2,2 2,22 2
2,2[(1 ) { ( ) (1 ) } ]
I I
iI p Var p p- - + -  
and 
2 2{ ( | )} 4[{ ( ) (1 ) } (1 ) ]vec I IiVar E T Var p p p= + - - - +p
2,1 2,122
2,
2
1 ( ) (1 ) } (1 ]{ )[
I I
iVar p p pI + - - - +
2,2 2,222
2,
2
2 ( ) (1 ) } (1 ]{ )[
I I
iVar p p pI + - - - +
98 
 
 
 
2,2 2,1 2,12
2 1
2
, (1 ) [{ ( ) (1 ) } (1 )4 ]
I I I
ip VaI r p p p- + - - - +
2,1 2,2 2,22
2 2
2
, (1 ) [{ ( ) (1 ) } (1 ) ].4
I I I
ip Var p p pI - + - - -  
Finally, we calculate 
2,2 2,1 2,1
2,1 2,2 2,2
2,1 2,1 2,2 2,2
2,1
2,2
2 2
2,1 2,2
( ) (1 ) {1 (1 ) } 4 (1 ) (1 ) {1 (1 ) }
4 (1 ) (1 ) {1 (1 ) }
(1 ) {1 (1 ) } (1 )
4
{1 (1 ) }
I I II I
I I I
I I I I
Var T p p I p p p
I p p p
I p p I p p
= - - - + - - - - +
- - - - +
- - - + - - -
 
( ).|TVar= p  
Similar to the results with the first moment, the variance for the number of tests 
is the same as when the individual probabilities are all equal.  
When more steps are used or when testing error is present, our conclusion is 
the same due to the independence of the pi random variables. Presenting the 
general argument only adds a considerable number of terms that greatly increase 
the algebraic complexity. Therefore, we have chosen not to show the most 
general case here. 
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Appendix C: Expected number of tests when 
p = 0.10, 0.01, and 0.005 
This appendix includes the figures for the p = 0.10, 0.01, and 0.005 cases 
discussed in Section 2.4.  
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Figure C.1. Mean number of tests for p = 0.1. Each row of panels corresponds to the number of halving steps. Each 
column of panels corresponds to specificity and sensitivity settings. 
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Figure C.2. Mean number of tests for p = 0.01. Each row of panels corresponds to the number of halving steps. Each 
column of panels corresponds to specificity and sensitivity settings. 
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Figure C.3. Mean number of tests for p = 0.005. Each row of panels corresponds to the number of halving steps. Each 
column of panels corresponds to specificity and sensitivity settings. 
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Appendix D: Chlamydia and gonorrhea 
expected tests and accuracy results using 
halving 
This appendix includes the additional results discussed in Section 2.5. Table 
D.1gives the sensitivities and specificities for each gender and specimen 
combination for gonorrhea. Tables D.2 to D.6show results for groups of size 8, 12, 
16, 24, and 32. Within each of these tables, the following are displayed:  
 
1. Number of tests,  
2. Pooling sensitivity (PSe) – Proportion of true positives that test positive 
through halving,  
3. Pooling specificity (PSp) – Proportion of true negatives that test negative 
through halving, 
4. Pooling positive predictive value (PPPV) – Proportion of individuals that 
test positive through halving who are truly positive, and   
5. Pooling negative predictive value (PNPV) – Proportion of individuals that 
test negative through halving who are truly negative. 
 
We average the above measures across ten implementations of halving to account 
for simulation variability that arises due to imperfect diagnostic tests. There are 
a few instances where unordered halving has slightly fewer tests than ordered 
halving. These are due to the simulation variability.  
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Table D.1. Information about gonorrhea testing. 
Se Sp 
Observed  
prevalence 
 Number of 
individuals screened 
Female Urine 
 
0.849 0.98 
 
2.0%  2,679 
 
Swab 
 
0.966 0.98 
 
1.0%  19,450 
Male Urine 
 
0.970 0.96 
 
1.6%  3,852 
 
Swab 
 
0.985 0.96 
 
4.9%  4,086 
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  Chlamydia Gonorrhea 
  
Tests PSe PSp PPPV PNPV Tests PSe PSp PPPV PNPV 
Urine 
Female 
Dorfman 1,557.7 0.65 0.98 0.82 0.96 708.1 0.73 1.00 0.84 0.99 
3-step unordered 1,238.9 0.51 0.99 0.89 0.95 579.9 0.62 1.00 0.95 0.99 
3-step ordered 1,236.3 0.53 0.99 0.89 0.95 580.0 0.62 1.00 0.95 0.99 
4-step unordered 1,228.5 0.44 1.00 0.96 0.94 564.6 0.52 1.00 0.98 0.99 
4-step ordered 1,207.8 0.43 1.00 0.96 0.94 568.4 0.52 1.00 0.96 0.99 
Urine 
Male 
Dorfman 2,415.6 0.87 0.98 0.78 0.99 1,050.8 0.93 0.99 0.74 1.00 
3-step unordered 2,009.0 0.81 0.99 0.87 0.98 862.2 0.91 1.00 0.91 1.00 
3-step ordered 1,971.8 0.81 0.99 0.87 0.98 862.6 0.91 1.00 0.91 1.00 
4-step unordered 1,996.4 0.75 1.00 0.95 0.98 857.2 0.87 1.00 0.97 1.00 
4-step ordered 1,965.2 0.74 1.00 0.95 0.98 859.2 0.87 1.00 0.95 1.00 
Swab 
Female 
Dorfman 9,492.6 0.86 0.99 0.80 0.99 4,164.8 0.94 1.00 0.85 1.00 
3-step unordered 7,833.0 0.80 0.99 0.90 0.99 3,560.0 0.90 1.00 0.94 1.00 
3-step ordered 7,705.8 0.80 0.99 0.90 0.99 3,548.4 0.91 1.00 0.94 1.00 
4-step unordered 7,804.2 0.74 1.00 0.95 0.98 3,550.4 0.88 1.00 0.98 1.00 
4-step ordered 7,731.2 0.74 1.00 0.96 0.98 3,545.0 0.88 1.00 0.98 1.00 
Swab 
Male 
Dorfman 2,984.6 0.87 0.97 0.83 0.98 1,915.0 0.97 0.99 0.79 1.00 
3-step unordered 2,633.8 0.79 0.99 0.89 0.97 1,600.8 0.95 0.99 0.89 1.00 
3-step ordered 2,534.6 0.79 0.99 0.90 0.97 1,572.4 0.96 0.99 0.91 1.00 
4-step unordered 2,721.6 0.75 0.99 0.95 0.96 1,609.4 0.94 1.00 0.96 1.00 
4-step ordered 2,639.0 0.74 0.99 0.95 0.96 1,596.2 0.94 1.00 0.96 1.00 
Table D.2. Additional results for the 2005 NPHL data with a group size of  8.  
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Chlamydia Gonorrhea 
  
Tests PSe PSp PPPV PNPV Tests PSe PSp PPPV PNPV 
Urine 
Female 
Dorfman 1,735.1 0.66 0.98 0.78 0.96 749.6 0.74 1.00 0.81 0.99 
3-step unordered 1,297.5 0.52 0.99 0.84 0.95 530.0 0.62 1.00 0.90 0.99 
3-step ordered 1,229.1 0.50 0.99 0.86 0.95 528.2 0.60 1.00 0.87 0.99 
4-step unordered 1,136.2 0.42 1.00 0.93 0.94 486.0 0.53 1.00 0.96 0.99 
4-step ordered 1,104.8 0.42 1.00 0.93 0.94 480.7 0.52 1.00 0.95 0.99 
Urine 
Male 
Dorfman 2,701.8 0.86 0.97 0.72 0.99 1091.4 0.95 0.99 0.66 1.00 
3-step unordered 2,109.2 0.80 0.98 0.81 0.98 787.2 0.92 1.00 0.82 1.00 
3-step ordered 2,076.8 0.80 0.98 0.82 0.98 792.6 0.93 1.00 0.85 1.00 
4-step unordered 1,908.0 0.74 0.99 0.91 0.98 736.0 0.89 1.00 0.90 1.00 
4-step ordered 1,884.2 0.73 0.99 0.91 0.98 726.5 0.87 1.00 0.93 1.00 
Swab 
Female 
Dorfman 10,791.9 0.86 0.98 0.75 0.99 3986.8 0.93 1.00 0.79 1.00 
3-step unordered 8,222.9 0.80 0.99 0.85 0.99 3058.1 0.91 1.00 0.91 1.00 
3-step ordered 8,007.2 0.79 0.99 0.85 0.99 3026.9 0.89 1.00 0.90 1.00 
4-step unordered 7,443.4 0.74 1.00 0.92 0.98 2874.3 0.88 1.00 0.96 1.00 
4-step ordered 7,242.8 0.73 1.00 0.93 0.98 2859.5 0.88 1.00 0.97 1.00 
Swab 
Male 
Dorfman 3,357.8 0.85 0.96 0.78 0.98 2219.0 0.97 0.98 0.75 1.00 
3-step unordered 2,840.0 0.79 0.98 0.85 0.97 1702.2 0.96 0.99 0.85 1.00 
3-step ordered 2,680.4 0.79 0.98 0.86 0.97 1675.8 0.96 0.99 0.86 1.00 
4-step unordered 2,666.1 0.74 0.99 0.92 0.96 1569.6 0.94 1.00 0.93 1.00 
4-step ordered 2,546.3 0.74 0.99 0.93 0.96 1526.1 0.93 1.00 0.93 1.00 
Table D.3. Additional results for the 2005 NPHL data with a group size of 12. 
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Chlamydia Gonorrhea 
  
Tests PSe PSp PPPV PNPV Tests PSe PSp PPPV PNPV 
Urine 
Female 
Dorfman 1,925.6 0.65 0.98 0.76 0.96 816.6 0.72 0.99 0.74 0.99 
3-step unordered 1,405.6 0.54 0.99 0.81 0.95 540.5 0.62 1.00 0.84 0.99 
3-step ordered 1,352.0 0.53 0.99 0.83 0.95 529.6 0.60 1.00 0.88 0.99 
4-step unordered 1,146.4 0.43 0.99 0.90 0.94 452.9 0.53 1.00 0.93 0.99 
4-step ordered 1,102.5 0.42 0.99 0.90 0.94 457.0 0.56 1.00 0.93 0.99 
5-step unordered 1,132.2 0.35 1.00 0.95 0.93 434.4 0.38 1.00 0.98 0.99 
5-step ordered 1,100.8 0.35 1.00 0.95 0.93 443.0 0.45 1.00 0.98 0.99 
Urine 
Male 
Dorfman 3,037.4 0.86 0.96 0.68 0.99 1152.2 0.94 0.99 0.65 1.00 
3-step unordered 2,338.2 0.80 0.98 0.78 0.98 796.6 0.92 1.00 0.80 1.00 
3-step ordered 2,253.2 0.81 0.98 0.78 0.98 798.4 0.91 1.00 0.81 1.00 
4-step unordered 2,000.0 0.76 0.99 0.88 0.98 690.2 0.89 1.00 0.91 1.00 
4-step ordered 1,930.6 0.75 0.99 0.88 0.98 689.8 0.89 1.00 0.91 1.00 
5-step unordered 1,992.9 0.69 1.00 0.95 0.97 687.7 0.85 1.00 0.94 1.00 
5-step ordered 1,946.8 0.70 1.00 0.95 0.97 692.4 0.86 1.00 0.96 1.00 
Swab 
Female 
Dorfman 12,341.1 0.86 0.98 0.70 0.99 4237.2 0.93 1.00 0.75 1.00 
3-step unordered 9,035.2 0.80 0.99 0.80 0.99 2938.6 0.89 1.00 0.89 1.00 
3-step ordered 8,759.5 0.80 0.99 0.81 0.99 2917.3 0.90 1.00 0.87 1.00 
4-step unordered 7,569.4 0.74 0.99 0.89 0.98 2612.2 0.87 1.00 0.94 1.00 
4-step ordered 7,404.9 0.75 0.99 0.90 0.98 2580.0 0.86 1.00 0.94 1.00 
5-step unordered 7,533.7 0.67 1.00 0.96 0.98 2591.4 0.83 1.00 0.98 1.00 
5-step ordered 7,387.7 0.69 1.00 0.96 0.98 2572.4 0.84 1.00 0.98 1.00 
Swab 
Male 
Dorfman 3,568.0 0.86 0.96 0.76 0.98 2542.4 0.97 0.98 0.71 1.00 
3-step unordered 2,996.4 0.79 0.97 0.82 0.97 1895.4 0.96 0.99 0.80 1.00 
3-step ordered 2,815.6 0.80 0.98 0.84 0.97 1794.6 0.96 0.99 0.82 1.00 
4-step unordered 2,638.4 0.72 0.99 0.89 0.96 1616.6 0.95 0.99 0.90 1.00 
4-step ordered 2,495.4 0.73 0.99 0.90 0.96 1545.4 0.94 0.99 0.91 1.00 
5-step unordered 2,702.4 0.67 1.00 0.95 0.95 1627.2 0.94 1.00 0.96 1.00 
5-step ordered 2,579.2 0.67 1.00 0.96 0.95 1583.8 0.94 1.00 0.96 1.00 
Table D.4. Additional results for the 2005 NPHL data with a group size of 16.  
  
 
 
108
Chlamydia Gonorrhea 
  
Tests PSe PSp PPPV PNPV Tests PSe PSp PPPV PNPV 
Urine 
Female 
Dorfman 2,114.5 0.66 0.97 0.72 0.96 1,018.3 0.70 0.99 0.68 0.99 
3-step unordered 1,540.3 0.55 0.98 0.78 0.95 597.9 0.63 1.00 0.83 0.99 
3-step ordered 1,502.8 0.54 0.98 0.80 0.95 598.5 0.59 1.00 0.81 0.99 
4-step unordered 1,161.3 0.43 0.99 0.84 0.94 434.6 0.49 1.00 0.90 0.99 
4-step ordered 1,115.4 0.43 0.99 0.86 0.94 436.0 0.49 1.00 0.92 0.99 
5-step unordered 1,018.4 0.33 1.00 0.92 0.93 401.9 0.45 1.00 0.96 0.99 
5-step ordered 1,019.7 0.35 1.00 0.91 0.93 397.6 0.43 1.00 0.96 0.99 
Urine 
Male 
Dorfman 3,277.4 0.87 0.96 0.67 0.99 1,411.4 0.94 0.99 0.55 1.00 
3-step unordered 2,598.4 0.81 0.97 0.74 0.98 907.0 0.91 0.99 0.69 1.00 
3-step ordered 2,519.2 0.80 0.97 0.74 0.98 902.8 0.90 0.99 0.71 1.00 
4-step unordered 2,092.5 0.75 0.99 0.82 0.98 701.2 0.87 1.00 0.83 1.00 
4-step ordered 2,022.0 0.76 0.99 0.82 0.98 698.2 0.89 1.00 0.84 1.00 
5-step unordered 1,935.3 0.70 0.99 0.91 0.97 650.3 0.86 1.00 0.92 1.00 
5-step ordered 1,857.6 0.71 0.99 0.91 0.97 645.9 0.89 1.00 0.94 1.00 
Swab 
Female 
Dorfman 14,481.7 0.86 0.97 0.65 0.99 5,000.8 0.93 1.00 0.68 1.00 
3-step unordered 10,448.6 0.79 0.98 0.74 0.99 3,166.1 0.90 1.00 0.82 1.00 
3-step ordered 9,957.0 0.80 0.98 0.76 0.99 3,093.4 0.90 1.00 0.82 1.00 
4-step unordered 8,115.7 0.74 0.99 0.85 0.98 2,488.5 0.88 1.00 0.92 1.00 
4-step ordered 7,745.4 0.74 0.99 0.86 0.98 2,425.0 0.86 1.00 0.91 1.00 
5-step unordered 7,368.4 0.69 1.00 0.92 0.98 2,315.5 0.85 1.00 0.96 1.00 
5-step ordered 7,107.1 0.69 1.00 0.93 0.98 2,278.5 0.85 1.00 0.97 1.00 
Swab 
Male 
Dorfman 3,819.0 0.86 0.96 0.74 0.98 3,058.2 0.97 0.97 0.64 1.00 
3-step unordered 3,325.0 0.80 0.97 0.78 0.97 2,252.4 0.96 0.98 0.74 1.00 
3-step ordered 2,998.6 0.79 0.97 0.80 0.97 2,061.6 0.96 0.98 0.77 1.00 
4-step unordered 2,832.2 0.74 0.98 0.86 0.96 1,757.8 0.93 0.99 0.85 1.00 
4-step ordered 2,607.4 0.75 0.98 0.86 0.96 1,608.6 0.94 0.99 0.88 1.00 
5-step unordered 2,616.2 0.68 0.99 0.92 0.95 1,618.3 0.93 1.00 0.92 1.00 
5-step ordered 2,471.8 0.69 0.99 0.93 0.95 1,514.6 0.93 1.00 0.93 1.00 
Table D.5. Additional results for the 2005 NPHL data with a group size of 24.  
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Chlamydia Gonorrhea 
  
Tests PSe PSp PPPV PNPV Tests PSe PSp PPPV PNPV 
Urine 
Female 
Dorfman 2,186.5 0.64 0.97 0.70 0.96 1,158.4 0.70 0.99 0.67 0.99 
3-step unordered 1,632.1 0.52 0.98 0.74 0.95 669.5 0.58 1.00 0.76 0.99 
3-step ordered 1,541.3 0.54 0.98 0.78 0.95 637.2 0.60 1.00 0.76 0.99 
4-step unordered 1,211.9 0.42 0.99 0.80 0.94 446.5 0.48 1.00 0.86 0.99 
4-step ordered 1,085.4 0.41 0.99 0.84 0.94 427.2 0.48 1.00 0.88 0.99 
5-step unordered 1,007.1 0.34 1.00 0.90 0.93 376.0 0.42 1.00 0.96 0.99 
5-step ordered 961.3 0.35 1.00 0.90 0.93 376.5 0.43 1.00 0.94 0.99 
Urine 
Male 
Dorfman 3,506.6 0.87 0.96 0.64 0.99 1,723.4 0.94 0.98 0.48 1.00 
3-step unordered 2,882.0 0.80 0.97 0.70 0.98 1,078.0 0.92 0.99 0.65 1.00 
3-step ordered 2,762.4 0.80 0.97 0.70 0.98 1,058.2 0.93 0.99 0.65 1.00 
4-step unordered 2,233.8 0.74 0.98 0.79 0.98 771.6 0.89 1.00 0.77 1.00 
4-step ordered 2,236.2 0.75 0.98 0.78 0.98 773.2 0.89 1.00 0.79 1.00 
5-step unordered 1,930.7 0.69 0.99 0.86 0.97 657.4 0.87 1.00 0.90 1.00 
5-step ordered 1,909.9 0.70 0.99 0.88 0.97 665.8 0.89 1.00 0.90 1.00 
Swab 
Female 
Dorfman 15,691.0 0.86 0.97 0.63 0.99 5,773.2 0.93 0.99 0.64 1.00 
3-step unordered 11,711.6 0.80 0.98 0.71 0.99 3,564.5 0.89 1.00 0.77 1.00 
3-step ordered 11,124.1 0.80 0.98 0.72 0.99 3,414.6 0.90 1.00 0.79 1.00 
4-step unordered 8,771.6 0.74 0.99 0.80 0.98 2,566.2 0.87 1.00 0.88 1.00 
4-step ordered 8,173.4 0.73 0.99 0.82 0.98 2,499.2 0.88 1.00 0.89 1.00 
5-step unordered 7,378.6 0.68 1.00 0.90 0.98 2,240.7 0.84 1.00 0.94 1.00 
5-step ordered 7,103.1 0.68 1.00 0.90 0.98 2,181.0 0.83 1.00 0.95 1.00 
Swab 
Male 
Dorfman 3,802.6 0.86 0.96 0.75 0.98 3,390.8 0.97 0.97 0.61 1.00 
3-step unordered 3,427.5 0.79 0.96 0.77 0.97 2,555.5 0.95 0.98 0.70 1.00 
3-step ordered 3,165.1 0.79 0.97 0.77 0.97 2,222.7 0.95 0.98 0.75 1.00 
4-step unordered 2,939.8 0.74 0.98 0.83 0.96 1,939.4 0.94 0.99 0.79 1.00 
4-step ordered 2,631.3 0.73 0.98 0.84 0.96 1,706.2 0.94 0.99 0.84 1.00 
5-step unordered 2,605.9 0.69 0.99 0.90 0.95 1,675.8 0.93 0.99 0.88 1.00 
5-step ordered 2,403.6 0.67 0.99 0.90 0.95 1,512.4 0.93 1.00 0.91 1.00 
Table D.6. Additional results for the 2005 NPHL data with a group size of 32.
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Appendix E: Hierarchical group testing 
examples for Sections 3.2 and 3.3 
Figure E.1provides an example of a possible five-stage hierarchical group testing 
procedure. There are many other possible hierarchical group testing procedures, 
and this is not meant to be an optimal configuration.  
At stage 1 within Figure, we have I11 = 10 individuals. If the initial group 
tests positive, c2 = m11 = 3 subgroups are formed with I21 = 4, I22 = 1, and I23 = 
5 individuals within each. Groups that test positive at stage 2 are further split 
into m21 = 2, m22 = 0 (because individual testing has already occurred), and m23 
= 2 sub-groups. This leads to at most c3 = 4 sub-groups that are tested with 
sizes I31 = 3, I32 = 1, I33 = 3, and I34 = 2. Groups that test positive at stage 3 are 
split into m31 = 2, m32 = 0, m33 = 2, and m34 = 2 sub-groups. This leads to at 
most c4 = 6 sub-groups of size I41 = 2, I42 = 1, I43 = 2, I44 = 1, I45 = 1, and I46 = 
1. Groups that test positive at stage 4 are split into m41 = 2, m42 = 0, m43 = 2, 
m44 = 0, m45 = 0, and m46 = 0 sub-groups. This leads to at most c5 = 4 sub-
groups of size I51 = 1, I52 = 1, I53 = 1, and I54 = 1. 
Figure E.2provides an example of a CRC for a case where I = 18. To find this 
configuration, we used individual probabilities that were the expected values of 
order statistics from a beta distribution with p = 0.05 and a = 0.10, which 
produces the set of E(p(i))s (0.0029, 0.0060, 0.0093, 0.0127, 0.0164, 0.0204, 0.0293, 
0.0344, 0.0400, 0.0463, 0.0534, 0.0616, 0.0714, 0.0835, 0.0993, 0.1224, 0.1662)(see 
Section 3.3). 
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Figure E.1. Five-stage hierarchical group testing example. 
 
I11 = 10, 
m11 = 3
s = 1, 
c1 = 1 
I21 = 4, 
m21 = 2
I22 = 1, 
m22 = 0
I23 = 5, 
m23 = 2
s = 2, 
c2 = 3 
s = 3, 
c3 = 4
I31 = 3, 
m31 = 2
I32 = 1, 
m32 = 0
I33 = 3, 
m33 = 2
I34 = 2, 
m34 = 2
I41 = 2, 
m41 = 2
I42 = 1, 
m42 = 0
I43 = 2, 
m43 = 2
I44 = 1, 
m44 = 0
I45 = 1, 
m45 = 0
I46 = 1, 
m46 = 0
I51 = 1, 
m51 = 0
I52 = 1, 
m52 = 0
I53 = 1, 
m53 = 0
I54 = 1, 
m54 = 0
s = 4, 
c4 = 6 
s = 5, 
c5 = 4
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Figure E.2. CRC with I = 18, p = 0.05, and a = 1. Due to the lack of space, the “1” in the last stage indicates I4j = 1 for 
j = 1, …, 13. Note that m4j = 0 for j = 1, …, 13. 
I11 = 18, 
m11 = 3
s = 1, 
c1 = 1 
I21 = 11, 
m21 = 3
I22 = 4, 
m22 = 3
I23 = 3, 
m23 = 3
s = 2, 
c2 = 3 
s = 3, 
c3 = 9 
I31 = 5, 
m31 = 5
I32 = 3, 
m32 = 3
I38 = 1, 
m38 = 0
I39 = 1, 
m39 = 0
s = 4, 
c4 = 13 
I33 = 3, 
m33 = 3
I37 = 1, 
m37 = 0
I36 = 1, 
m36 = 0
I35 = 1, 
m35 = 0
I34 = 2, 
m34 = 2
1 111111111111
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Appendix F: Convexity of Equation (3.1) 
The purpose of this appendix is to show there are situations when Equation (3.2) 
is convex upward as a function of the number of subgroups and their sizes.  
Figure F.1 displays a simple example for three separate situations where I = 
35, Se = Sp = 1, and c2 = 2. Case 1 involves pi = 0.05 for all i and convexity 
holds. Case 2 involves pi = 0.15 for all i, and convexity fails. Case 3 involves the 
E(p(i))s from a beta distribution where p = 0.15 and a = 1.2, and convexity fails.  
Overall, we have found problems with convexity occur in extreme situations 
where the initial group is very likely to test positive, because the initial group 
size is large and/or the overall prevalence is high. For example, the probability 
that the initial group tests positive for case 2 is 351 (1 0.15) 0.9966- - = . These 
extreme situations generally did not occur in the comparisons of Section 3 and in 
the IPP example of Section 4, which led to the CRC almost always being the 
same as the ORC. Unfortunately, due to the large number of factors – such as 
initial group size, sensitivity and specificity levels, number of sub-groups, and 
potentially I different individual probabilities – we found developing general 
conditions for convexity to be intractable. 
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Figure F.1. E(T) for the examples in Appendix F. Case 1 involves pi = 0.05 for all i, case 2 involves pi = 0.15 for all i, and 
case 3 involves the E(p(i))s from a beta distribution where p = 0.15 and a = 1.2. 
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Appendix G: Candidate retesting 
configurations for Section 3.3 
Candidate retesting configurations for Section 3.3, Tables G.1 to G.4provide the 
three-stage CRCs and Tables G.5 to G.14provide the four-stage CRCs. 
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a0 
 
a= 0.10 
 
a= 1 
 
a¥ 
I 
 
E(T)/I I21 I22 I23 
 
E(T)/I I21 I22 I23 
 
E(T)/I I21 I22 I23 I24 
 
E(T)/I I21 I22 I23 I24 
5 
 
0.2425 4 1 
  
0.2484 4 1 
  
0.2599 4 1 
   
0.2644 3 2 
  
6 
 
0.2067 5 1 
 
0.2155 5 1 
  
0.2290 4 2 
   
0.2314 3 3 
  
7 
 
0.1815 6 1 
 
0.1933 6 1 
  
0.2074 5 2 
   
0.2103 4 3 
  
8 
 
0.1628 7 1 
 
0.1781 7 1 
  
0.1912 5 3 
   
0.1945 4 4 
  
9 
 
0.1486 8 1 
 
0.1659 7 1 1 
 
0.1797 6 3 
   
0.1842 5 4 
  
10 
 
0.1376 9 1 
 
0.1554 7 2 1 
 
0.1717 6 3 1 
  
0.1759 5 5 
  
11 
 
0.1288 10 1 
 
0.1467 8 2 1 
 
0.1645 6 3 2 
  
0.1689 4 4 3 
 
12 
 
0.1218 11 1 
 
0.1398 9 2 1 
 
0.1585 6 4 2 
  
0.1627 4 4 4 
 
13 
 
0.1161 12 1 
 
0.1341 9 3 1 
 
0.1536 6 4 3 
  
0.1588 5 4 4 
 
14 
 
0.1115 13 1 
 
0.1293 10 3 1 
 
0.1496 7 4 3 
  
0.1554 5 5 4 
 
15 
 
0.1078 14 1 
 
0.1254 11 3 1 
 
0.1468 8 4 3 
  
0.1526 5 5 5 
 
16 
 
0.1048 15 1 
 
0.1223 12 3 1 
 
0.1445 8 5 3 
  
0.1511 6 5 5 
 
17 
 
0.1024 16 1 
 
0.1199 13 3 1 
 
0.1429 9 5 3 
  
0.1495 5 4 4 4 
18 
 
0.1004 16 1 1 
 
0.1181 14 3 1 
 
0.1417 9 5 4 
  
0.1480 5 5 4 4 
19 
 
0.0976 17 1 1 
 
0.1163 14 4 1 
 
0.1404 7 5 4 3 
 
0.1466 5 5 5 4 
20 
 
0.0951 18 1 1 
 
0.1148 15 4 1 
 
0.1389 8 5 4 3 
 
0.1454 5 5 5 5 
Table G.1. Group sizes for three-stage CRCs for p = 0.01. 
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a0 
 
a= 0.10 
 
a= 1 
 
a¥ 
I 
 
E(T)/I I21 I22 I23 
 
E(T)/I I21 I22 I23 I24 
 
E(T)/I I21 I22 I23 I24 
 
E(T)/I I21 I22 I23 I24 I25 
5 
 
0.3351 4 1 
  
0.3555 4 1 
   
0.3984 3 1 1 
  
0.4206 3 2 
   
6 
 
0.3085 5 1 
  
0.3374 5 1 
   
0.3815 4 1 1 
  
0.3992 3 3 
   
7 
 
0.2937 6 1 
  
0.3197 5 1 1 
  
0.3703 4 2 1 
  
0.3937 4 3 
   
8 
 
0.2869 7 1 
  
0.3080 6 1 1 
  
0.3641 4 3 1 
  
0.3873 3 3 2 
  
9 
 
0.2764 7 1 1 
 
0.3025 7 1 1 
  
0.3608 5 3 1 
  
0.3798 3 3 3 
  
10 
 
0.2663 8 1 1 
 
0.2968 7 2 1 
  
0.3626 5 3 1 1 
 
0.3805 4 3 3 
  
11 
 
0.2589 9 1 1 
 
0.2931 8 2 1 
  
0.3620 5 3 2 1 
 
0.3809 4 3 4 
  
12 
 
0.2537 10 1 1 
 
0.2913 8 3 1 
  
0.3622 5 3 3 1 
 
0.3810 4 4 4 
  
13 
 
0.2504 11 1 1 
 
0.2885 9 3 1 
  
0.3623 6 3 3 1 
 
0.3847 4 3 3 3 
 
14 
 
0.2487 12 1 1 
 
0.2870 9 3 1 1 
 
0.3624 6 4 3 1 
 
0.3859 4 4 3 3 
 
15 
 
0.2464 12 2 1 
 
0.2842 10 3 1 1 
 
0.3646 7 4 3 1 
 
0.3867 4 4 4 3 
 
16 
 
0.2432 13 2 1 
 
0.2826 11 3 1 1 
 
0.3671 7 4 3 2 
 
0.3873 4 4 4 4 
 
17 
 
0.2405 14 2 1 
 
0.2822 12 3 1 1 
 
0.3685 7 4 3 3 
 
0.3913 5 4 4 4 
 
18 
 
0.2385 15 2 1 
 
0.2821 12 4 1 1 
 
0.3701 7 5 3 3 
 
0.3948 5 5 4 4 
 
19 
 
0.2370 16 2 1 
 
0.2817 13 4 1 1 
 
0.3713 7 5 4 3 
 
0.3966 4 4 4 4 3 
20 
 
0.2361 17 2 1 
 
0.2820 14 4 1 1 
 
0.3729 8 5 4 3 
 
0.3968 4 4 4 4 4 
Table G.2. Group sizes for three-stage CRCs for p = 0.05. 
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a0 
 
a= 0.10 
 
a= 1 
 
a¥ 
I 
 
E(T)/I I21 I22 I23 I24 
 
E(T)/I I21 I22 I23 I24 I25 
 
E(T)/I I21 I22 I23 I24 I25 I26 
 
E(T)/I I21 I22 I23 I24 I25 
5 
 
0.4665 4 1 
   
0.4912 4 1 
    
0.5434 3 1 1 
    
0.5924 3 2 
   
6 
 
0.4590 5 1 
   
0.4710 4 1 1 
   
0.5406 4 1 1 
    
0.5792 3 3 
   
7 
 
0.4363 5 1 1 
  
0.4562 5 1 1 
   
0.5392 4 2 1 
    
0.5836 3 2 2 
  
8 
 
0.4204 6 1 1 
  
0.4522 6 1 1 
   
0.5386 4 3 1 
    
0.5785 3 3 2 
  
9 
 
0.4114 7 1 1 
  
0.4516 6 2 1 
   
0.5389 4 3 1 1 
   
0.5733 3 3 3 
  
10 
 
0.4083 8 1 1 
  
0.4478 7 2 1 
   
0.5407 5 3 1 1 
   
0.5793 4 3 3 
  
11 
 
0.4075 8 2 1 
  
0.4407 7 2 1 1 
  
0.5444 5 3 2 1 
   
0.5834 4 4 3 
  
12 
 
0.4002 9 2 1 
  
0.4345 8 2 1 1 
  
0.5453 5 3 3 1 
   
0.5818 3 3 3 3 
 
13 
 
0.3921 10 1 1 1 
 
0.4279 8 3 1 1 
  
0.5471 5 4 3 1 
   
0.5858 4 3 3 3 
 
14 
 
0.3826 10 2 1 1 
 
0.4228 9 3 1 1 
  
0.5487 6 4 3 1 
   
0.5886 4 4 3 3 
 
15 
 
0.3730 11 2 1 1 
 
0.4202 10 3 1 1 
  
0.5503 6 4 3 1 1 
  
0.5904 4 4 4 3 
 
16 
 
0.3650 12 2 1 1 
 
0.4196 10 3 1 1 1 
 
0.5523 6 4 3 2 1 
  
0.5915 4 4 4 4 
 
17 
 
0.3589 13 2 1 1 
 
0.4150 11 3 1 1 1 
 
0.5513 6 4 3 3 1 
  
0.5951 4 4 3 3 3 
18 
 
0.3542 13 3 1 1 
 
0.4119 11 4 1 1 1 
 
0.5530 7 4 3 3 1 
  
0.5959 4 4 3 4 3 
19 
 
0.3477 14 3 1 1 
 
0.4082 12 4 1 1 1 
 
0.5540 7 4 4 3 1 
  
0.5963 4 4 4 4 3 
20 
 
0.3422 15 3 1 1 
 
0.4060 13 4 1 1 1 
 
0.5553 7 4 4 3 1 1 
 
0.5962 4 4 4 4 4 
Table G.3. Group sizes for three-stage CRCs for p = 0.10.  
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a0  a= 0.10  a= 1  a¥ 
I 
 
E(T)/I I21 I22 I23 I24 I25 I26 
 
E(T)/I I21 I22 I23 I24 I25 I26 
 
E(T)/I I21 I22 I23 I24 I25 I26 I27 
 
E(T)/I I21 I22 I23 I24 I25 I26 
5 
 
0.6047 4 1 
     
0.6137 3 1 1 
    
0.6685 3 1 1 
     
0.7407 3 2 
    
6 
 
0.5707 4 1 1 
    
0.5855 4 1 1 
    
0.6745 4 1 1 
     
0.7306 3 3 
    
7 
 
0.5488 5 1 1 
    
0.5762 5 1 1 
    
0.6761 4 1 1 1 
    
0.7364 3 2 2 
   
8 
 
0.5403 6 1 1 
    
0.5793 5 1 1 1 
   
0.6743 4 2 1 1 
    
0.7313 3 3 2 
   
9 
 
0.5386 6 1 1 1 
   
0.5640 6 1 1 1 
   
0.6710 4 3 1 1 
    
0.7253 3 3 3 
   
10 
 
0.5173 7 1 1 1 
   
0.5527 6 2 1 1 
   
0.6746 5 3 1 1 
    
0.7319 4 3 3 
   
11 
 
0.5039 8 1 1 1 
   
0.5423 7 2 1 1 
   
0.6763 5 3 1 1 1 
   
0.7346 3 3 3 2 
  
12 
 
0.4897 8 2 1 1 
   
0.5335 7 3 1 1 
   
0.6768 4 3 3 1 1 
   
0.7283 3 3 3 3 
  
13 
 
0.4772 9 2 1 1 
   
0.5252 8 3 1 1 
   
0.6733 5 3 3 1 1 
   
0.7320 4 3 3 3 
  
14 
 
0.4693 10 2 1 1 
   
0.5141 8 3 1 1 1 
  
0.6731 5 4 3 1 1 
   
0.7342 4 4 3 3 
  
15 
 
0.4551 10 2 1 1 1 
  
0.5049 9 3 1 1 1 
  
0.6731 5 4 3 1 1 1 
  
0.7306 3 3 3 3 3 
 
16 
 
0.4422 11 2 1 1 1 
  
0.4997 10 3 1 1 1 
  
0.6730 6 4 3 1 1 1 
  
0.7323 4 3 3 3 3 
 
17 
 
0.4328 11 3 1 1 1 
  
0.4940 10 3 1 1 1 1 
 
0.6704 5 4 3 3 1 1 
  
0.7332 4 4 3 3 3 
 
18 
 
0.4227 12 3 1 1 1 
  
0.4874 11 3 1 1 1 1 
 
0.6687 6 4 3 3 1 1 
  
0.7311 3 3 3 3 3 3 
19 
 
0.4147 13 3 1 1 1 
  
0.4812 11 4 1 1 1 1 
 
0.6674 6 4 3 3 1 1 1 
 
0.7316 4 3 3 3 3 3 
20 
 
0.4079 13 3 1 1 1 1 
 
0.4767 12 4 1 1 1 1 
 
0.6668 6 4 4 3 1 1 1 
 
0.7317 4 4 3 3 3 3 
Table G.4. Group sizes for three-stage CRCs for p = 0.15. 
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a 0 
 
a = 0.1 
I 
 
E(T)/I I21 I22 
 
I31 I32 
 
E(T)/I I21 I22 I23 
 
I31 I32 I33 I34 
5 
 
0.2404 4 1 
 
3 1 
 
0.2445 4 1 
  
3 1 
  
6 
 
0.2037 5 1 
 
4 1 
 
0.2092 5 1 
  
4 1 
  
7 
 
0.1775 6 1 
 
5 1 
 
0.1848 6 1 
  
5 1 
  
8 
 
0.1579 7 1 
 
6 1 
 
0.1669 7 1 
  
5 1 1 
 
9 
 
0.1427 8 1 
 
7 1 
 
0.1530 8 1 
  
6 1 1 
 
10 
 
0.1306 9 1 
 
8 1 
 
0.1424 9 1 
  
7 1 1 
 
11 
 
0.1207 10 1 
 
9 1 
 
0.1338 10 1 
  
7 2 1 
 
12 
 
0.1125 11 1 
 
10 1 
 
0.1269 11 1 
  
8 2 1 
 
13 
 
0.1056 12 1 
 
11 1 
 
0.1213 12 1 
  
9 2 1 
 
14 
 
0.0997 13 1 
 
12 1 
 
0.1166 13 1 
  
9 3 1 
 
15 
 
0.0946 14 1 
 
13 1 
 
0.1127 14 1 
  
10 3 1 
 
16 
 
0.0902 15 1 
 
14 1 
 
0.1095 15 1 
  
11 3 1 
 
17 
 
0.0864 16 1 
 
15 1 
 
0.1069 16 1 
  
12 3 1 
 
18 
 
0.0830 17 1 
 
16 1 
 
0.1044 16 1 1 
 
12 3 1 
 
19 
 
0.0800 18 1 
 
17 1 
 
0.1022 17 1 1 
 
13 3 1 
 
20 
 
0.0773 19 1 
 
18 1 
 
0.1002 18 1 1 
 
13 3 1 1 
Table G.5. Group sizes for four-stage CRC with p = 0.01 for a 0 and a = 0.1. 
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a = 1 a  ¥ 
I E(T)/I I21 I22 
 
I31 I32 I33 I34 I35 I36 E(T)/I I21 I22 
 
I31 I32 I33 I34 I35 I36 
5 0.2566 4 1 
 
3 1 
    
0.2654 3 2 
 
2 1 1 1 
  
6 0.2241 5 1 
 
3 1 1 
   
0.2322 3 3 
 
1 1 1 2 1 
 
7 0.2022 6 1 
 
3 2 1 
   
0.2094 3 4 
 
1 1 1 2 2 
 
8 0.1859 7 1 
 
4 2 1 
   
0.1929 4 4 
 
2 2 2 2 
  
9 0.1733 7 2 
 
4 2 1 1 1 
 
0.1802 4 5 
 
2 2 3 2 
  
10 0.1635 8 2 
 
4 3 1 1 1 
 
0.1701 5 5 
 
3 2 3 2 
  
11 0.1557 8 3 
 
4 3 1 1 1 1 0.1618 6 5 
 
3 3 3 2 
  
12 0.1492 9 3 
 
4 3 2 1 1 1 0.1549 6 6 
 
3 3 3 3 
  
13 0.1439 10 3 
 
5 3 2 1 1 1 0.1503 7 6 
 
3 4 3 3 
  
14 0.1396 10 4 
 
5 3 2 2 1 1 0.1461 6 8 
 
3 3 3 3 2 
 
15 0.1359 11 4 
 
5 3 3 2 1 1 0.1423 6 9 
 
3 3 3 3 3 
 
16 0.1329 12 4 
 
6 3 3 2 1 1 0.1394 7 9 
 
4 3 3 3 3 
 
17 0.1303 13 4 
 
6 4 3 2 1 1 0.1366 8 9 
 
2 3 3 3 3 3 
18 0.1280 13 5 
 
6 4 3 3 1 1 0.1339 9 9 
 
3 3 3 3 3 3 
19 0.1262 13 6 
 
6 4 3 3 2 1 0.1324 9 10 
 
3 3 3 3 4 3 
20 0.1246 14 6 
 
7 4 3 3 2 1 0.1310 10 10 
 
3 4 3 3 4 3 
Table G.6. Group sizes for four-stage CRC with p = 0.01 fora = 1 and a ¥. 
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a 0 
 
a = 0.1 
I 
 
E(T)/I I21 I22 I23 
 
I31 I32 I33 
 
E(T)/I I21 I22 I23 
 
I31 I32 I33 I34 I35 I36 
5 
 
0.3232 4 1 
  
3 1 
  
0.3381 4 1 
  
3 1 
    
6 
 
0.2885 5 1 
  
4 1 
  
0.3093 5 1 
  
4 1 
    
7 
 
0.2645 6 1 
  
5 1 
  
0.2924 6 1 
  
5 1 
    
8 
 
0.2475 7 1 
  
6 1 
  
0.2788 7 1 
  
5 1 1 
   
9 
 
0.2353 8 1 
  
7 1 
  
0.2702 8 1 
  
6 1 1 
   
10 
 
0.2265 9 1 
  
8 1 
  
0.2654 9 1 
  
7 1 1 
   
11 
 
0.2205 10 1 
  
9 1 
  
0.2584 9 1 1 
 
7 1 1 
   
12 
 
0.2147 11 1 
  
9 1 1 
 
0.2526 10 1 1 
 
7 2 1 
   
13 
 
0.2097 12 1 
  
10 1 1 
 
0.2484 11 1 1 
 
8 2 1 
   
14 
 
0.2058 13 1 
  
11 1 1 
 
0.2456 12 1 1 
 
8 3 1 
   
15 
 
0.2028 14 1 
  
12 1 1 
 
0.2432 13 1 1 
 
9 3 1 
   
16 
 
0.2006 15 1 
  
13 1 1 
 
0.2418 14 1 1 
 
10 3 1 
   
17 
 
0.1960 15 1 1 
 
13 1 1 
 
0.2413 15 1 1 
 
11 3 1 
   
18 
 
0.1915 16 1 1 
 
14 1 1 
 
0.2405 16 1 1 
 
11 3 1 1 
  
19 
 
0.1876 17 1 1 
 
15 1 1 
 
0.2403 17 1 1 
 
12 3 1 1 
  
20 
 
0.1842 18 1 1 
 
16 1 1 
 
0.2399 17 2 1 
 
12 3 1 1 1 1 
Table G.7. Group sizes for four-stage CRC with p = 0.05 for a 0 and a = 0.1. 
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a = 1 a  ¥ 
I E(T)/I I21 I22 I23 
 
I31 I32 I33 I34 I35 I36 I37 I38 I39 E(T)/I I21 I22 I23 
 
I31 I32 I33 I34 I35 I36 I37 
5 0.3914 4 1 
  
2 1 1 
      
0.4281 3 2 
  
2 1 1 1 
   
6 0.3712 5 1 
  
3 1 1 
      
0.4051 3 3 
  
1 1 1 2 1 
  
7 0.3594 5 1 1 
 
3 1 1 
      
0.3938 4 3 
  
2 1 1 1 1 1 
 
8 0.3527 5 2 1 
 
3 1 1 1 1 
    
0.3882 5 3 
  
3 2 1 1 1 
  
9 0.3475 6 2 1 
 
3 2 1 1 1 
    
0.3832 3 6 
  
1 1 1 3 3 
  
10 0.3442 7 2 1 
 
4 2 1 1 1 
    
0.3796 4 6 
  
2 2 3 3 
   
11 0.3409 7 3 1 
 
4 2 1 1 1 1 
   
0.3757 6 5 
  
3 3 2 3 
   
12 0.3393 8 3 1 
 
4 3 1 1 1 1 
   
0.3722 6 6 
  
3 3 3 3 
   
13 0.3389 9 3 1 
 
4 3 2 1 1 1 
   
0.3737 7 6 
  
2 3 2 3 3 
  
14 0.3390 10 3 1 
 
5 3 2 1 1 1 
   
0.3726 8 6 
  
3 3 2 3 3 
  
15 0.3398 11 3 1 
 
5 3 3 1 1 1 
   
0.3712 6 9 
  
3 3 3 3 3 
  
16 0.3402 11 3 2 
 
5 3 3 1 1 1 1 1 
 
0.3717 6 4 6 
 
3 3 2 2 3 3 
 
17 0.3401 11 3 3 
 
5 3 3 1 1 1 1 1 1 0.3700 6 5 6 
 
3 3 3 2 3 3 
 
18 0.3389 11 4 3 
 
5 3 3 2 1 1 1 1 1 0.3683 6 6 6 
 
3 3 3 3 3 3 
 
19 0.3386 11 5 3 
 
5 3 3 3 2 1 1 1 
 
0.3701 6 7 6 
 
3 3 3 4 3 3 
 
20 0.3385 11 6 3 
 
5 3 3 3 3 1 1 1 
 
0.3698 6 8 6 
 
3 3 3 3 2 3 3 
Table G.8. Group sizes for four-stage CRC with p = 0.05 fora = 1 and a ¥. 
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a 0 
 
a = 0.1 
I 
 
E(T)/I I21 I22 I23 I24 
 
I31 I32 I33 
 
E(T)/I I21 I22 I23 I24 
 
I31 I32 I33 I34 I35 I36 
5 
 
0.4339 4 1 
   
3 1 
  
0.4549 4 1 
   
3 1 
    
6 
 
0.4042 5 1 
   
4 1 
  
0.4341 5 1 
   
4 1 
    
7 
 
0.3866 6 1 
   
5 1 
  
0.4224 6 1 
   
4 1 1 
   
8 
 
0.3775 7 1 
   
6 1 
  
0.4112 6 1 1 
  
5 1 
    
9 
 
0.3693 8 1 
   
6 1 1 
 
0.3975 7 1 1 
  
5 1 1 
   
10 
 
0.3553 8 1 1 
  
7 1 
  
0.3881 8 1 1 
  
6 1 1 
   
11 
 
0.3437 9 1 1 
  
8 1 
  
0.3825 9 1 1 
  
6 2 1 
   
12 
 
0.3322 10 1 1 
  
8 1 1 
 
0.3775 10 1 1 
  
7 2 1 
   
13 
 
0.3227 11 1 1 
  
9 1 1 
 
0.3750 11 1 1 
  
8 2 1 
   
14 
 
0.3151 12 1 1 
  
10 1 1 
 
0.3731 11 1 1 1 
 
8 2 1 
   
15 
 
0.3095 13 1 1 
  
11 1 1 
 
0.3675 12 1 1 1 
 
8 3 1 
   
16 
 
0.3045 14 1 1 
  
11 2 1 
 
0.3628 13 1 1 1 
 
9 3 1 
   
17 
 
0.3003 15 1 1 
  
12 2 1 
 
0.3599 14 1 1 1 
 
10 3 1 
   
18 
 
0.2942 15 1 1 1 
 
12 2 1 
 
0.3569 15 1 1 1 
 
10 3 1 1 
  
19 
 
0.2863 16 1 1 1 
 
13 2 1 
 
0.3549 16 1 1 1 
 
11 3 1 1 
  
20 
 
0.2796 17 1 1 1 
 
14 2 1 
 
0.3524 16 2 1 1 
 
11 3 1 1 1 1 
Table G.9. Group sizes for four-stage CRC with p = 0.10 for a 0 and a = 0.1. 
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a = 1 
I E(T)/I I21 I22 I23 I24 
 
I31 I32 I33 I34 I35 I36 I37 I38 I39 I3,10 
5 0.5395 3 1 1 
  
2 1 
        
6 0.5261 4 1 1 
  
2 1 1 
       
7 0.5193 5 1 1 
  
3 1 1 
       
8 0.5207 5 2 1 
  
3 1 1 1 1 
     
9 0.5210 6 2 1 
  
3 2 1 1 1 
     
10 0.5194 6 3 1 
  
3 2 1 1 1 1 
    
11 0.5187 7 3 1 
  
4 2 1 1 1 1 
    
12 0.5190 8 3 1 
  
4 3 1 1 1 1 
    
13 0.5191 8 3 1 1 
 
4 3 1 1 1 1 
    
14 0.5203 9 3 1 1 
 
4 3 2 1 1 1 
    
15 0.5206 8 3 3 1 
 
4 3 1 1 1 1 1 1 1 
 
16 0.5195 9 3 3 1 
 
4 3 2 1 1 1 1 1 1 
 
17 0.5192 10 3 3 1 
 
5 3 2 1 1 1 1 1 1 
 
18 0.5190 11 3 3 1 
 
5 3 3 1 1 1 1 1 1 
 
19 0.5194 11 4 3 1 
 
5 3 3 1 1 1 1 1 1 1 
20 0.5190 10 6 3 1 
 
5 3 2 3 3 1 1 1 
  
Table G.10. Group sizes for four-stage CRC with p = 0.10 fora = 1. 
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a ¥ 
I E(T)/I I21 I22 I23 
 
I31 I32 I33 I34 I35 I36 I37 I38 I39 
5 0.6086 3 2 
  
2 1 1 1 
     
6 0.5923 3 3 
  
1 2 1 1 1 
    
7 0.5875 3 4 
  
1 1 1 2 1 1 
   
8 0.5878 3 3 2 
 
1 1 1 2 1 1 1 
  
9 0.5814 3 3 3 
 
1 1 1 2 1 1 1 1 
 
10 0.5808 3 4 3 
 
1 1 1 2 1 1 1 1 1 
11 0.5841 3 5 3 
 
1 1 1 3 2 1 1 1 
 
12 0.5840 3 6 3 
 
1 1 1 3 3 1 1 1 
 
13 0.5856 3 4 6 
 
1 1 1 1 1 1 1 3 3 
14 0.5862 3 5 6 
 
1 1 1 3 2 3 3 
  
15 0.5843 6 6 3 
 
3 3 3 3 1 1 1 
  
16 0.5842 6 6 4 
 
3 3 3 3 1 1 1 1 
 
17 0.5832 6 5 6 
 
3 3 3 2 3 3 
   
18 0.5807 6 6 6 
 
3 3 3 3 3 3 
   
19 0.5827 6 7 6 
 
3 3 3 2 2 3 3 
  
20 0.5814 6 8 6 
 
3 3 3 3 2 3 3 
  
Table G.11. Group sizes for four-stage CRC with p = 0.10 fora ¥. 
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a 0 
 
a = 0.1 
I 
 
E(T)/I I21 I22 I23 I24 I25 
 
I31 I32 I33 
 
E(T)/I I21 I22 I23 I24 I25 
 
I31 I32 I33 I34 I35 I36 
5 
 
0.5474 4 1 
    
3 1 
  
0.5701 4 1 
    
3 1 
    
6 
 
0.5249 5 1 
    
4 1 
  
0.5574 5 1 
    
4 1 
    
7 
 
0.5103 5 1 1 
   
4 1 
  
0.5307 5 1 1 
   
4 1 
    
8 
 
0.4828 6 1 1 
   
5 1 
  
0.5132 6 1 1 
   
4 1 1 
   
9 
 
0.4642 7 1 1 
   
6 1 
  
0.4983 7 1 1 
   
5 1 1 
   
10 
 
0.4475 8 1 1 
   
6 1 1 
 
0.4904 8 1 1 
   
6 1 1 
   
11 
 
0.4343 9 1 1 
   
7 1 1 
 
0.4850 8 1 1 1 
  
6 1 1 
   
12 
 
0.4255 10 1 1 
   
8 1 1 
 
0.4728 9 1 1 1 
  
6 2 1 
   
13 
 
0.4128 10 1 1 1 
  
8 1 1 
 
0.4631 10 1 1 1 
  
7 2 1 
   
14 
 
0.3985 11 1 1 1 
  
9 1 1 
 
0.4573 11 1 1 1 
  
8 2 1 
   
15 
 
0.3880 12 1 1 1 
  
9 2 1 
 
0.4526 12 1 1 1 
  
8 3 1 
   
16 
 
0.3791 13 1 1 1 
  
10 2 1 
 
0.4445 12 1 1 1 1 
 
8 3 1 
   
17 
 
0.3728 14 1 1 1 
  
11 2 1 
 
0.4377 13 1 1 1 1 
 
9 3 1 
   
18 
 
0.3641 14 1 1 1 1 
 
11 2 1 
 
0.4325 14 1 1 1 1 
 
9 3 1 1 
  
19 
 
0.3544 15 1 1 1 1 
 
12 2 1 
 
0.4284 15 1 1 1 1 
 
10 3 1 1 
  
20 
 
0.3471 16 1 1 1 1 
 
13 2 1 
 
0.4235 14 3 1 1 1 
 
10 3 1 1 1 1 
Table G.12. Group sizes for four-stage CRC with p = 0.15 for a 0 and a = 0.1. 
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a = 1 
I 
 
E(T)/I I21 I22 I23 I24 I25 I26 
 
I31 I32 I33 I34 I35 I36 I37 I38 I39 
5 
 
0.6642 3 1 1 
    
2 1 
       
6 
 
0.6547 4 1 1 
    
2 1 1 
      
7 
 
0.6510 5 1 1 
    
3 1 1 
      
8 
 
0.6538 5 1 1 1 
   
3 1 1 
      
9 
 
0.6539 5 2 1 1 
   
3 1 1 1 1 
    
10 
 
0.6513 5 3 1 1 
   
3 1 1 1 1 1 
   
11 
 
0.6490 6 3 1 1 
   
3 2 1 1 1 1 
   
12 
 
0.6479 7 3 1 1 
   
4 2 1 1 1 1 
   
13 
 
0.6474 8 3 1 1 
   
4 3 1 1 1 1 
   
14 
 
0.6465 8 3 1 1 1 
  
4 3 1 1 1 1 
   
15 
 
0.6460 7 3 3 1 1 
  
4 2 1 1 1 1 1 1 1 
16 
 
0.6425 8 3 3 1 1 
  
4 3 1 1 1 1 1 1 1 
17 
 
0.6409 9 3 3 1 1 
  
4 3 2 1 1 1 1 1 1 
18 
 
0.6399 9 3 3 1 1 1 
 
4 3 2 1 1 1 1 1 1 
19 
 
0.6386 10 3 3 1 1 1 
 
4 3 3 1 1 1 1 1 1 
20 
 
0.6371 11 3 3 1 1 1 
 
5 3 3 1 1 1 1 1 1 
Table G.13. Group sizes for four-stage CRC with p = 0.15 fora = 1. 
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a  ¥ 
I E(T)/I I21 I22 I23 I24 I25 
 
I31 I32 I33 I34 I35 I36 I37 I38 I39 I3,10 I3,11 I3,12 I3,13 I3,14 I3,15 I3,16 
5 0.7665 3 2 
    
2 1 1 1 
            
6 0.7517 3 3 
    
1 1 1 2 1 
           
7 0.7475 4 3 
    
2 1 1 1 1 1 
          
8 0.7465 3 3 2 
   
1 1 1 2 1 1 1 
         
9 0.7387 3 3 3 
   
1 1 1 2 1 1 1 1 
        
10 0.7367 3 4 3 
   
1 1 1 2 1 1 1 1 1 
       
11 0.7404 4 4 3 
   
1 1 1 1 2 1 1 1 1 1 
      
12 0.7381 3 3 3 3 
  
1 1 1 2 1 1 1 1 1 1 1 
     
13 0.7354 3 4 3 3 
  
1 1 1 1 1 2 1 1 1 1 1 1 
    
14 0.7374 3 3 4 4 
  
1 1 1 1 1 1 1 1 2 1 1 1 1 
   
15 0.7368 3 6 3 3 
  
1 1 1 3 3 1 1 1 1 1 1 
     
16 0.7372 3 6 4 3 
  
1 1 1 3 3 1 1 1 1 1 1 1 
    
17 0.7357 3 4 3 4 3 
 
1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 
18 0.7343 3 6 3 3 3 
 
1 1 1 3 3 1 1 1 1 1 1 1 1 1 
  
19 0.7341 3 9 3 4 
  
1 1 1 3 3 3 1 1 1 1 1 1 1 
   
20 0.7334 3 9 4 4 
  
1 1 1 3 3 3 1 1 1 1 1 1 1 1 
  
Table G.14. Group sizes for four-stage CRC with p = 0.15 fora ¥. 
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Appendix H: Additional accuracy summaries 
for Section 3.3 
Corresponding to the discussion in Section 3.3, Figures H.1, H.2 and H.3give the 
accuracy measures with p = 0.01, 0.10, and 0.15, respectively. 
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Figure H.1. Accuracy measures when p = 0.01 and Se = Sp = 0.95. 
a  0, S = 3
a  0, S = 4
a = 0.1,  S = 3 a  ∞, S = 3
a = 0.1,  S = 4
a = 1,  S = 3
a = 1,  S = 4 a  ∞, S = 4
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Figure H.2. Accuracy measures when p = 0.10 and Se = Sp = 0.95. 
a  0, S = 3
a  0, S = 4
a = 0.1,  S = 3 a  ∞, S = 3
a = 0.1,  S = 4
a = 1,  S = 3
a = 1,  S = 4 a  ∞, S = 4
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Figure H.3. Accuracy measures when p = 0.15 and Se = Sp = 0.95.
a  0, S = 3
a  0, S = 4
a = 0.1,  S = 3 a  ∞, S = 3
a = 0.1,  S = 4
a = 1,  S = 3
a = 1,  S = 4 a  ∞, S = 4
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Appendix I: R function documentation 
Vector of probabilities produced from a beta distribution. 
Description 
Produces a vector of expected ordered statistics for a random sample of a specified size from a 
beta distribution  
Usage 
 
beta.dist(p, alpha = 1, beta = NULL, grp.sz = 10, simul = FALSE,
 rel.tol = ifelse(alpha < 1, .Machine$double.eps^0.1, 
 .Machine$double.eps^0.25),  plot = FALSE) 
Arguments 
p a probability value; if the value is between 0 and 1, it is used as mean of the beta 
random variable  
alpha value for alpha in the beta distribution. If alpha = “hom” or “inf”, a homogeneous 
vector of probabilities is produced. If alpha = 0, the Bernoulli distribution is used. 
beta if p = NULL or not a value between 0 and 1, b is the beta value for the beta distribution 
grp.sz number of probabilities to produce 
simul finds the expected order statistics through simulation instead of using the PDFs 
rel.tol used in integrate() function; may need to change for different values of alpha 
plot returns a plot of the associated beta distribution with expected ordered values 
indicated, only works for the beta distributions 
Details 
Produces a vector of probabilities  
Value 
p.vec vector of probabilities 
Author(s) 
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Michael Black, Christopher R Bilder 
Examples 
 
p1 <- beta.dist(p = 0.05, alpha = 1, grp.sz = 16, plot = TRUE)  
  round(p1, 4)  
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Descriptive information for the halving group testing procedure up to 5 stages. 
Description 
Obtains PMF for the possible number of tests to identify all positive individuals in a group using 
the “halving” group testing procedure. Returns the PMF, expected value, and variance.  
Usage 
 
halving(p, se = 1, sp = 1, stages = 2, order.p = TRUE) 
Arguments 
p a vector of individual probabilities 
se, sp sensitivity and specificity, respectively  
stages number of stages for hierarchical group testing 
order.p default is TRUE indicating the values in p are sorted; FALSE leaves the individual 
probabilities in their given order 
Details 
The PMF is produced for a vector of individual probabilities.  
Value 
PMF data frame with number of tests and associated probabilities 
ET expected number of tests 
VT variance of number of tests 
Author(s) 
Michael Black, Christopher R Bilder 
Examples 
 
ex1 <- halving(p = rep(x = 0.05, times = 16), stages = 3) 
ex1 
ex2 <- halving(p = rep(x = 0.05, times = 16), stages = 3, se = 0.95,  
  sp = 1) 
p1 <- beta.dist(p = 0.05, a = 1, b = NULL, grp.sz = 16) 
ex3 <- halving(p = p1, stages = 3, se = 0.95, sp = 1, order.p = TRUE) 
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data.frame(t = ex1$pmf[,1], ex1 = ex1$pmf[,2], ex2 = ex2$pmf[,2], ex3 
  = ex3$pmf[,2], row.names = NULL)  #PMF 
data.frame(ex1 = ex1$et, ex2 = ex2$et, ex3 = ex3$et) #E(T) 
data.frame(ex1 = ex1$vt, ex2 = ex2$vt, ex3 = ex3$vt) #Var(T) 
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Diagnostic information for generalized hierarchical group testing procedure. 
Description 
Returns diagnostic information for a given vector of probabilities for 2, 3, or 4 stages. 
Usage 
 
hierarchical.desc(p, se = 1, sp = 1, I2 = NULL, I3 = NULL, order.p =  
  TRUE) 
Arguments 
p a vector of individual probabilities 
se, sp sensitivity and specificity, respectively 
stages number of stages for hierarchical group testing 
I2 vector of stage 2 subgroup sizes 
I3 vector of stage 3 subgroup sizes 
order.p default is TRUE indicating informative retesting; FALSE leaves the individual 
probabilities in their given order 
Details 
Produces the diagnostic information. Pooling diagnostic information is for the given group. If the 
group is part of a larger retesting process, individual diagnostic values should be used for the 
entire process to calculate the pooling diagnostic values.  
Value 
ET expected number of tests 
group.size I2, I3 vectors with number of individuals in each subgroup 
m1, m2, m3 vectors with number of subgroups a group splits into 
individual.testerror table of individual pooled accuracy measures 
group.testerror vector of pooled accuracy measures for the group 
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Author(s) 
Michael Black, Christopher R Bilder 
Examples 
 
p1 <- beta.dist(p = 0.05, a = 1, b = NULL, grp.sz = 16) 
ex4 <- hierarchical.desc(p = p1, se = 0.95, sp = 1, I2 = c(8, 8), I3 
 = NULL) 
ex4  
140 
 
 
 
Optimal or candidate retesting configuration. 
Description 
Finds the optimal configuration (ORC) or a possible optimal configuration (CRC) for retesting over 
2, 3 or 4 stages  
Usage 
 
get.CRC(p, se = 1, sp = 1, stages = 2, order.p = TRUE, everycase =  
  FALSE, init.config = “hom”) 
Arguments 
P a vector of individual probabilities 
se, sp sensitivity and specificity, respectively 
stages number of stages for hierarchical group testing 
order.p default is TRUE indicating informative retesting; FALSE leaves the individual 
probabilities in their given order 
everycase default is FALSE indicating the CRC is found; TRUE finds ORC, warning of 
possible excessive time. 
init.config default is “hom” which uses an initial configuration with subgroups of 
approximately equal sizes;  “ord” uses an initial configuration with 1 individual in 
each subgroup except the first; “both” uses both “hom” and “ord” methods 
Details 
ORC can require an excessive amount of running time for large groups (>18 for three stages, >13 
for four stages). If a group has fairly homogeneous probabilities then init.config = “hom” 
should be used. If a group has very heterogeneous probabilities init.config = “ord” should 
be used. 
Value 
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ORC Returned if everycase = TRUE 
CRC Returned if everycase = FALSE 
Desc Provides diagnostic values from hierarchical.desc
Author(s) 
Michael Black, Christopher R Bilder 
Examples 
 
p1 <- beta.dist(p = 0.05, a = 1, b = NULL, grp.sz = 16) 
ex5 <- get.CRC(p = p1, se = .95,sp = 1, stages = 3) 
ex5 
 
 
 
